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Abstracts of invited paperst
Symposium on The Cell Biology of Tumour/
Stroma Interactions
Extraceliular matrix influence on gene expression: Is
structure the message?
Mina J. Bissell
Lab Cell Biology, Div. of Biology & Medicine, Lawrence
Berkeley Laboratory, Berkeley, CA 94720, USA.
Mammary epithelial cells from midpregnant mouse have
been used as a model to show that extracellular matrix
(ECM) and some of its components (laminin, and heparan
sulfate proteoglycan) play a fundamental role in regulation
of milk protein synthesis and secretion. Using mouse and
human c-DNA clones as well as polyclonal and monoclonal
antibodies to the casein gene family (a, # and y), transferrin,
whey acidic protein and a-lactalbumin, we have shown that
the ECM regulates milk proteins at multiple points: (a)
mRNA level; (b) protein synthesis and accumulation; (c)
secretory rate and route; (d) the level and the nature of
proteolytic activities, (3) hormonal inducibility and (4) lumen
formation and vectorial secretion. Thus, a complex interplay
between hormones, ECM and 'shape' determine whether or
not a given protein is synthesized and how it is secreted. The
results are consistent with a model of 'dynamic reciprocity'
where ECM is proposed to influence gene expression via
transmembrane proteins attached to cytoskeleton-in turn
with connections to the nuclear matrix. A disruption of this
interaction at any regulatory point will lead to destabiliza-
tion of the differentiated state and may be a promotional
event in cancer induction.
Extracellular matrix in intestinal morphogenesis and
differentiation
P. Simon-Assmann, F. Bouziges, K. Haffen & M. Kedinger
INSERM Unite 61, Avenue Moliere 67200 Strasbourg,
France.
Intestinal organogenesis and differentiation are driven by
interactions between the endoderm and the mesenchyme. The
developmental pattern of heterospecific or heterotopic recom-
binants between epithelial-mesenchymal anlagen allowed us
to elucidate the respective role of both tissue components in
morphogenesis, epithelial differentiation and hormone-elicited
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responses. The endoderm is induced by the mesenchyme to
differentiate into the polarized epithelial cell types character-
istic of the intestine. Intramucosal fibroblasts of the differen-
tiated intestine retain properties similar to embryonic
mesenchyme.
Among the mechanisms of tissue interactions, the possible
mediation of information via the extracellular matrix is
postulated. Positive arguments are brought about by the
observation of compositional changes in matrix molecules
during intestinal development and differentiation. Immunocy-
tochemistry shows that basement membrane (BM) compo-
nents are present at the epithelial-mesenchymal interface
early in embryonic development and that changes in the
spatial distribution of some extracellular matrix proteins
within the mesenchyme are associated with morphogenetic
processes. Cocultured or transplanted intestinal epithelial-
mesenchymal cell associations allowed us to show (1) that
cell contacts between both cell populations are essential for
deposition of BM components in a polar fashion at their
interface; (2) the major role of the mesenchyme in the
deposition of type IV collagen in BM and in remodelling of
the glycosaminoglycans (GAG), mainly of hyaluronic chains.
The question whether epithelial cells in tumours synthesize
different rates of ECM molecules or induce the adjacent
mesenchymal cells to modify their synthetic pattern has been
tested. Using human HT29 colon carcinoma cells, we could
show that the shift from undifferentiated (sugar-containing
medium) to differentiated cells (sugar-free medium) was
accompanied by (1) an enhancement in the overall GAG
synthesis; (2) the appearance of a new class of chondroitin,
Cs4 sulfate; (3) a modification in the charge density of the
heparan sulfate molecule. No major modifications in the
synthetic properties of the mesenchymal cell compartment
were obvious when HT29 cells were cocultured with skin
fibroblasts.
Taken together, the different experiments stress the impor-
tance of the mesenchymal compartment in tissue interactions
which take place in intestinal development and differentia-
tion. The search for perturbations of the epithelial-
mesenchymal interactions in cancer is currently under study.
Keratin expression and epithelial cell differentiation
E.B. Lane
Cell Structure Laboratory, ICRF Clare Hall Laboratories,
Blanche Lane, South Mimms, Potter's Bar, Hertfordshire
EN63LD, UK.
Monoclonal antibodies can contribute an extra level of
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resolution to histology, in that the use of certain monoclo-
nals in immunohistochemistry will sometimes reveal sub-
populations of physiologically distinct cells within what
appears to be a homogeneous tissue by conventional histolo-
gical staining. Recent observations show that this is particu-
larly true of epithelial tissues. We are currently applying
monoclonal antibodies which are specific for single keratin
intermediate filament proteins, as they become available, to
an analysis of keratin expression in situ in the study of
epithelial differentiation. Expression of any pair or pairs of
type I+type II keratins, of the 30 or so keratins described in
human tissues, is characteristic of a particular state (or
states) of differentiation, and intermediate filament expres-
sion appears to be one of the earlier decisions made after
induction of differentiation during the course of developmen-
tal organogenesis. In complex stratified epithelia we have
observed that keratin expression also changes during the
course of regeneration after wounding, and that keratin
expression in tumours frequently resembles that of wound-
healing situations. The data suggest that the intermediate
filament phenotype is fundamental to tissue function,
perhaps because of a dominant effect on tissue structure.
The major question regarding intermediate filaments is still
that of the evolutionary pressure which could drive the
establishment of such extensive heterogeneity within this
gene family: How do these filaments work? To look for
functional differences between keratins and to investigate
how tissue specificity might be effected, we are using
bacterially-produced recombinant keratin fragments to
investigate keratin subdomains, using mapped monoclonal
antibodies as probes for defined regions of the keratin
molecules.
Structure and function of the cytoskeletal proteins alpha-
actinin and vinculin
D.R. Critchley, G.J. Price, P. Jones & M.D. Davison
Department of Biochemistry, University of Leicester,
Leicester LE] 7RH, UK.
Vinculin and alpha-actinin are cytoskeletal proteins found in
a family of specialised cell-cell and cell-substrate contacts
called adherens junctions where they serve (along with a
number of other components) to link microfilamentous actin
to the membrane. Much of the interest in these structures
stems from the observation that the interactions between the
various cytoskeletal proteins is disrupted following tumour-
virus transformation or exposure of cells to tumour pro-
moters or growth factors. A detailed understanding of the
mechanisms underlying these events has been limited by a
lack of information on the structure of the cytoskeletal
proteins involved. We have now determined the sequence of
chick alpha-actinin (Baron et al., J. Biol. Chem., 262, 17623,
1987) and vinculin (Price et al., Biochem. J., 245, 595, 1987)
and have begun to identify the functional domains in these
two proteins. Thus residues 1-240 of alpha-actinin contain
the actin binding domain; 240-740 contains four 120 residue
repeats which show homology to those in the cytoskeletal
protein spectrin; the C-terminus of the protein contains two
EF-hand calcium binding sites. Interestingly, the Duchenne
muscular dystrophy protein contains a homologous actin-
binding domain and spectrin-like repeats. Analysis of the
deduced vinculin sequence shows that residues 259-589
consist of three 112 amino acid repeats contained within the
globular head region of the molecule which is released by V8
proteinase as a 90 kDa-fragment. This fragment contains the
N-terminus of vinculin and the talin-binding domain. The
V8 cleavage site (Leu 858) is contained within a proline-rich
region which separates the vinculin head from the extended
tail. There is a candidate tyrosine phosphorylation site
(Tyr 822) at the head/tail junction.
Symposium on 'Control of Gene Expression
by Sequence Recognition'
Sponsored by Bristol-Myers Oncology UK Ltd.
Sequence recognition by antibiotics and its structural
consequences
M.J. Waring
Department of Pharmacology, University of Cambridge,
Hills Road, Cambridge CB22QD, UK.
Echinomycin and other members of the quinoxaline group of
antibiotics bind to DNA by a mechanism of bifunctional
(bis-) intercalation. Footprinting experiments have revealed
that they associate preferentially with sequences in natural
DNA containing the dinucleotide step CpG, though this
requirement cannot be mandatory because binding also
occurs to poly dG.poly dC and to poly (dA-dT). The
molecular basis of sequence recognition is indicated by X-ray
crystallographic studies. Features of the antibiotics which are
critical for recognising the preferred base-pair sequences
include peptide N-methylation as well as the CO and NH
functionalities of the L-alanine residues in the octapeptide
ring. Sequences flanking the antibiotic binding sites are
subject to conformational changes which can be seen in
footprinting patterns and by enhanced reactivity to chemical
reagents; they may involve Hoogsteen base pairing.
Addition of echinomycin to reconstituted nucleosome core
particles containing labelled DNA produces striking changes
in the nuclease digestion pattern. Strong bands, representing
new nuclease-sensitive sites, appear which cannot be attrib-
uted to simple displacement of DNA from the protein core.
Fourier analysis of the perturbed digestion pattern suggests
that antibiotic binding causes a shift in the positioning of
DNA with respect to the histone octamer, equivalent to
rotation of the entire polynucleotide by about half a turn.
This change in rotational orientation occurs with eukaryotic
as well as prokaryotic DNA fragments and can be seen after
binding of other, non-intercalating, antibiotics such as
netropsin and distamycin.
Development of sequence specific DNA effectors
J.W. Lown
Department of Chemistry, University of Alberta, Edmonton,
Alberta, Canada T6G2G2
Alternative approaches to the problem of developing DNA
sequence specific agents for potential use in diagnosis and
therapy of cancer are reviewed. The major problems of
oligonucleotide probes, i.e. difficulty of cellular uptake and
susceptibility to intracellular degradation, suggested as poss-
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ible alternatives the employment of certain oligopeptide
agents. Progress in the development of lexitropsins, or
information-reading oligopeptides which bind selectively to
the minor groove of duplex nucleic acids, is discussed. The
ability to engineer lexitropsins to recognize and bind to
predetermined sequences, their ready cellular uptake, and
concentration in the cell nucleus, may offer advantages in
the development of cellular regulatory agents. The anticancer
efficacy of prototype sequence specific minor groove alkyla-
tors is described.
1988 Walter Hubert Lecture
Artificial regulation of gene expression by oligonucleotides
covalently linked to intercalating agents
C. Helene
Laboratoire de Biophysique, Museum National d'Histoire
Naturelle, INSERM U.201, CNRS UA.481, 61 Rue Buffon,
75005 Paris, France.
Oligonucleotides can be used to block mRNA translation.
Covalent attachment of intercalating agents to oligodeoxy-
nucleotides provides an additional binding energy which
strongly enhances hybrid formation with complementary
sequences. In addition oligonucleotide-intercalator conjugates
exhibit an increased penetration across cell membranes and
are protected against exonucleases. These modified oligo-
deoxynucleotides can be used to block gene expression both
in vitro and in vivo. Their effect on protein synthesis is - at
least in part - mediated by an RNaseH-induced degradation
of mRNA in the oligodeoxynucleotide-mRNA hybrid.
The nuclease resistance of oligodeoxynucleotides can be
markedly improved by using as building blocks synthetic [a]-
anomers of nucleosides instead of the natural [f]-anomers.
Oligo-[a]-deoxynucleotides form double helices with comple-
mentary DNA sequences in which the two strands adopt a
parallel orientation.
[a]- and [,B]-oligodeoxynucleotides can be covalently
attached to reactive groups which can be activated either
chemically or photochemically to generate irreversible reac-
tions in their target sequence.
The major groove of the DNA double helix can be
selectively recognized by oligopyrimidines which form a local
triple helix at homopurine-homopyrimidine sequences. The
oligopyrimidine is oriented parallel to the purine-containing
strand. Irreversible reactions can be achieved on the native
DNA double helix. This opens the way for selective regula-
tion of gene expression at the transcriptional level.
Control of gene expression by oligonucleoside
methylphosphonates
P.S. Miller, K.R. Blake, J.M. Kean, B.L. Lee, S.B. Lin, A.
Murakami & P.O.P. Ts'o
Division of Biophysics, School of Hygiene and Public
Health, The Johns Hopkins University, Baltimore, MD,
USA.
Our laboratory has studied the use of antisense oligonucleo-
side methylphosphonates (OMPs) to control gene expression
at the mRNA level in living cells. These analogs contain
nuclease resistant, methylphosphonate internucleoside bonds;
form stable, hydrogen-bonded complexes with complemen-
tary sequences of single-stranded RNA and DNA; and are
taken up intact by mammalian cells in culture. OMPs
targeted against initiation codon regions of vesicular stomati-
tis virus mRNAs or against the acceptor splice junction
regions of two Herpes simplex type 1 precursor mRNAs
specifically inhibit virus function in virus-infected cells in a
sequence dependent manner. We have also prepared OMPs
derivatized with 4'-N(2-aminoalkyl)-aminomethyl-4,5', 8-
trimethylpsoralen, photoactivatable crosslinking groups.
These oligomers specifically crosslink with targeted mRNA
upon irradiation at 365nm and specifically inhibit mRNA
translation in cell free systems at low (1-5MM) concent-
rations. A psoralen-derivatized oligomer complementary to
the initiation codon region of VSV N-protein mRNA inhi-
bits VSV protein synthesis at 5 uM concentration when VSV-
infected cells are irradiated in the presence of the oligomer.
Because OMPs are very stable in media containing mamma-
lian serum and are readily taken up by mammalian cells,
they should be quite useful as antisense agents in cell culture
experiments and possibly in experiments involving animals.
It appears that psoralen-derivatized OMPS may be particu-
larly effective as inhibitors and that they could be used to
help define the cellular target(s) of the oligomers and thus
the mechanism of action of the oligomers in cell culture
systems.
Synthesis and evaluation of N-ras anti-sense and nonsense
methylphosphonate oligonucleotide analogues
D. Tiddl, P. Hawley2 & I. Gibson2
'Department of Radiation Oncology, Clatterbridge Hospital,
Wirral, Merseyside and 2School of Biological Sciences,
University of East Anglia, Norwich NR47TJ, UK.
Anti-sense 8-mer nonionic methylphosphonate oligonucleo-
tide analogues have been reported to inhibit target gene
expression in intact cells by virtue of their ability to (i) cross
cell membranes, (ii) resist nuclease degradation, and (iii)
form sequence specific hybrids with mRNA (Miller & Ts'o,
Anti-Cancer Drug Design, 2, 117, 1987). We are interested in
using this approach as a means of investigating the relation
between oncogene expression and maintenance of the trans-
formed phenotype. A methylphosphonate 9-mer anti-sense to
codons 1-3 of the human N-ras gene and a 'nonsense'
scramble of this sequence were synthesized by both the
phosphotriester analogous and the new methylphosphonami-
dite chemistries. The two oligonucleotide analogues were
shown by MIT assay to be completely non-toxic to human
HT29 cells in culture at concentrations of up to 80 uM, and
in addition, we confirmed by HPLC analysis that no detec-
table degradation of the molecules occurred in cultures over
48 h. A phosphodiester oligodeoxynucleotide 20-mer corres-
ponding in sequence to codons 1-7 of the human N-ras gene
was used to investigate the hybridization properties of the
methylphosphonates in solution. At low temperature (<5°C)
both anti-sense and nonsense analogues formed 1:1 com-
plexes with the 20-mer probe, but these were largely disso-
ciated at 25°C. Only a fraction (10-20%) of the molecules in
the anti-sense preparations formed stable hybrids with the
20-mer. This could conceivably mean that most of the 256
diastereoisomeric forms present in the purified 9-mer were
unable to form Watson-Crick base pairing interactions along
their entire length. The melting temperature of the hybrids
which did form was approximately 34°C. Our preliminary
cell culture results were not repeated in subsequent experi-
ments, which showed no effect of the anti-sense oligonucleo-
tide on induction of p2lN-raS protein synthesis by
dexamethasone in T15 cells, a line of NIH3T3 cells trans-
fected with multiple copies of the human N-ras gene under
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Pyrrolo(1,4)benzodiazepine antitumour antibiotics. Sequence
specificity and effect of binding on local DNA structure
L.H. Hurley & L. Boyd
Drug Dynamics Institute, College of Pharmacy, University
of Texas at Austin, Austin, TX78712, USA.
Anthramycin and tomaymycin are members of the pyrrolo-
(1,4)benzodiazepine antibiotic group. These drugs bind cova-
lently in the minor groove of DNA through N2 of guanine.
Previous studies have shown that PuGPu sequences are the
most favoured for binding, while PyGPy sequences are least
favoured. Using a combination of fluorescence, 1H and 31p_
NMR, and molecular modelling studies we have examined
the binding of tomaymycin and anthramycin to -various
oligomers including d(ATGCAT)2. While anthramycin only
forms one type of adduct with the duplex, tomaymycin
forms two adducts in approximately equal amounts. Anthra-
mycin binds via a 11S linkage geometry with the aromatic
ring to the 3' side of the covalently modified guanine, while
tomaymycin binds with either an 11S or 11R linkage geo-
metry. Molecular modelling and 1H-NMR studies suggest
that the IlS isomer binds in the 3' orientation while the IIR
isomer binds in the 5' orientation. Upon binding of anthra-
mycin to DNA the covalently modified strand undergoes a
selective conformational change up to three bases to the 3'
side of the adduct. At the covalent linkage site the glycosidic
dihydral angle is dramatically changed and the pucker of the
sugar to the 3' side assumes the unusual C4'-endo conforma-
tion. The sugar-phosphate backbone torsion angles between
the covalently modified guanine and the two bases to the 3'
side also appear to have undergone changes resulting in
significant changes in the base to H ' and H2' and H2"
distances and downfield shifts of the 31P-NMR signals.
New DNA-interactive molecules: Rational design by
computer modelling
T.C. Jenkins, R. Newman, L.H. Pearl, A. Walton, G.D.
Webster & S. Neidle
CRC Biomolecular Structure Unit, The Institute of Cancer
Research, Sutton, Surrey SM25PX, UK.
Computer graphics modelling and molecular mechanics cal-
culations are powerful tools for studying intermolecular
interactions. We have been applying these techniques to the
design of analogues of the DNA groove binding molecule
berenil which have potentially altered sequence recognition
properties. The scope and limitations of the approach will be
discussed, and results compared with those obtained
experimentally.
Abstracts of Members' Proffered Papers -
Oral presentations
NIH-3T3 cells can be transformed by transfection with DNA
from transplanted rat hepatomas but not primary rat
hepatomas
M.J. Embleton, A. Stibbe & P.C. Butler
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG72RD, UK.
NIH-3T3 cells were transfected with DNA extracted from
chemically-induced primary and syngeneically transplanted
rat hepatomas using a calcium phosphate co-precipitation
method, in order to assess the ability of the DNA to induce
transformation. Negative control DNA was prepared from
NIH-3T3 cells and normal rat liver, and a positive control
was provided by EJF-5, a line of NIH-3T3 transformed by
DNA from human bladder carcinoma cells. The EJF-5 DNA
and DNA from two transplanted rat hepatomas originally
induced by oral 4-dimethylaminoazobenzene (DAB) pro-
duced transformation of NIH-3T3 recognised as piled-up
foci in monolayer cultures and by clonogenicity in soft agar,
while liver DNA and NIH-3T3 DNA produced none at all.
DNA from four primary hepatomas induced by DAB and
five induced by oral 2-acetylaminofluorene failed to trans-
form NIH-3T3. These DNA preparations were able to
transfer the APRT+ phenotype into LM clone 11 APRT-
cells, however, so they were active with respect to other
genes. It was concluded that transforming genes were not
detectable in the DNA of primary rat hepatomas, but
became expressed as part of the progression or selection
process accompanying repeated transplantation. It is sug-
gested that the more vigorous growth (hence more 'malig-
nant'behaviour) of such selected cell populations may be
associated with greater expression of activated oncogenes in
comparison with the mean level in primary tumours.
Suppression of tumorigenicity in cells transfected with DNA
from non-neoplastic cells
D. Tarin', A. J. Hayle, J. Taggart1 & P.A. Whittaker2
'Nuffield Department of Pathology, John Radcliffe Hospital,
Headington, Oxford OX3 9DU and 2Department of
Biochemistry, University of Oxford, UK.
This study investigated whether transfer of DNA from non-
neoplastic cells into tumour cells could suppress tumour
formation, by supplying regulatory genes, postulated to be
deleted or damaged in malignant cells. Total genomic DNA
from normal human blood leucocytes was co-transfected
with the gene for neomycin resistance (neoR) into the highly
tumorigenic mouse fibrosarcoma cell line (TR4Nu).
Controls consisted of cells co-transfected with their own
DNA, or with DNA from various human and animal
tumour lines and neoR. Clones surviving after selection in
neomycin were expanded separately and inoculated s.c. into
nude mice. These were observed until tumours arose or for
180 days, whichever was sooner. Non-transfected clones of
TR4Nu all (24/24) formed s.c. tumours with a mean latent
period of 28 days. Similarly rapid 100% tumorigenicity was
observed for the various control clones transfected with
mouse or human tumour DNA (41/41). However, of the 34
clones tested, transfected with normal human DNA, one
(XDI.6) exhibited marked inhibition of tumorigenicity and
was demonstrated to contain exogenous DNA by Southern
blotting and probing with neoR and with a probe for human
repetitive sequences (Blur 8). The earliest tumour arising was
not observed until 100 days while some animals did not
develop tumours at all within the 180 day observation
period. The mean latent period of tumorigenicity among
animals that did develop tumours was 127 days. TheseTWENTY-NINTH ANNUAL MEETING OF THE BRITISH ASSOCIATION FOR CANCER RESEARCH 227
observations indicate that tumorigenicity can be suppressed
or inhibited by sequences transferred from the normal
genome. It has not escaped our notice that these findings, if
corroborated, have therapeutic implications.
Characterisation of clonal cell populations after transfection
of metastatic DNA
A.J. Haylel, P.A. Whittaker2 & D. Tarin'
'Nuffield Department of Pathology, John Radcliffe Hospital,
Headington, Oxford OX39DU and 2Department of
Biochemistry, University of Oxford, UK.
Transfection of total genomic DNA from the highly metasta-
tic mouse histiocytic sarcoma (M5076) line into a non-
metastatic mouse fibrosarcoma cell line (TR4Nu), resulted
in the establishment of clones which showed the capability to
overwhelmingly colonise the lungs when inoculated i.v. into
nude mice. Of the 5 clones tested, one produced metastatic
colonisation of the lungs in 17/22 (77%) nude mice tested,
another clone resulted in 16/21 (76%) showing colonisation,
whilst the remaining 3 clones showed 6/22 (27%), 5/23
(21%) and 0/22 animals with metastatic lesions. One clone
was also spontaneously metastatic in 1/8 (12.5%) nude mice
tested from a tumour formed after s.c. inoculation. Since the
experiment involved transfection of mouse cell DNA into
another mouse cell line, the DNA from the donor cells was
first cloned into a cosmid library to aid recognition and
recovery of transferred sequences. The cosmid used
(PCV108) also contained the gene for resistance to neomycin
(neoR) as a selectable marker. Transfections were performed
using polybrene and DMSO and survival of cell clones in
neomycin containing medium provided initial evidence of
exogenous DNA incorporation. By using nick translated
isolated neo sequences to probe Southern blot transfers of
the DNA from these clones, we have confirmed the presence
of cosmid vector sequences (and therefore by inference
transfected M5076 DNA) in the transfected cells. Multiple
incorporation patterns of the cosmid library were seen which
were unique to specific clones. These results confirm prev-
ious findings indicating that components of the metastatic
phenotype can be dominantly conferred on previously non-
metastatic tumour cells by transfer of genomic DNA.
Further, they may enable isolation and identification of
genes believed to be involved in metastatic behaviour.
Metastasis and the increased expression of MHC class I
molecules. A possible mechanism for how the primary site
could affect tumour spread
M. Blackmore1, S. Thompsoni, C.G. Brooks2 & G.A.
Turnerl
Departments of Clinical Biochemistry and 2 Pathology, The
Medical School, University of Newcastle upon Tyne, UK.
Interactions at the primary site of tumour growth could be
very important in affecting metastasis. Recent studies (Karre
et al., Br. J. Cancer., 36, 503, 1985) have suggested that
interferon-stimulated MHC expression may be linked to
increased metastasis via reduced NK cell recognition. In the
current study we provide further support for this proposal,
and present evidence to suggest that this mechanism could
be operating in vivo and explain the observed variation in
metastasis with primary implantation site. Class I molecules
(KbDb) were not detected on the surface of cultured murine
melanoma cells (B16-BL6) using cell surface radiolabelling,
immunoprecipitation and electrophoresis. This finding was
further confirmed by screening mRNA isolated from BL6
cells with synthetic oligonucleotide probes to class I
sequences. However, class I molecules were detected if the
cells were grown s.c. and then reintroduced into culture. In
other experiments, treatment of MHC-negative cells with
IFN-y (10-10,000 Uml-') induced class I expression (as
measured by immunoprecipitation), and the acquisition of
sensitivity to anti-Kb-specific cytotoxic T cells) but caused an
almost complete loss of sensitivity to syngeneic NK cells.
When these cells were injected intravenously they formed
twice as many lung colonies (15 control mice: median=41;
15 treated mice: median=80). In the s.c. site, the treated
cells appeared to grow faster but this finding is very
preliminary and no similar effect was observed for cells
growing in vitro. IFN-ac/, also increased class I expression
but this was much less than observed with IFN-y. These
studies suggest that there may be a direct relationship
between high MHC class I expression, loss of NK sensitivity
and the metastatic spread of tumours in this system.
Possible autocrine control of growth and progression of
melanoma by a-MSH
J. Lunec', C. Fisher2, C. Parker', G.V. Sherbet' & A.J.
Thody2
'Cancer Research Unit, University of Newcastle upon Tyne,
Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP
and 2Department of Dermatology, University of Newcastle
upon Tyne, Newcastle upon Tyne NE] 4LP, UK.
Melanocyte stimulating hormone (MSH) regulates pigment
cells and recent evidence suggests that in the case of
melanoma cells it stimulates anchorage independent growth
and metastatic capacity. In this study, we have examined the
possibility that melanoma cells produce MSH.
Immunoreactive a-MSH was detected in several variants
of the B16 murine melanoma. Levels ranged from
339+81pglO 6 cells (n=9) in BL6 cells to 445+69pg10-6
cells (n=7) in FIO cells. As shown by HPLC, most of the
immunoreactivity corresponded to desacetyl and monacety-
lated a-MSH. No immunoreactivity was detected
(<20 pg 10-6 cells) in 3T3, A431 cell lines and in normal
keratinocytes and melanocytes.
Additional evidence for the expression of ac-MSH by B16
melanomas has also been obtained at the transcriptional
level. A full length cDNA probe for the murine pro-
opiomelanocorticotropin (POMC) gene transcript, which
includes the a-MSH coding sequence, was used to detect the
presence of POMC cDNA clones in a AgtIO bacteriophage
cDNA library made using mRNA isolated from the BL6
high metastasis variant of the B16 melanoma. Strong posi-
tive signals were obtained under high stringency hybridisa-
tion conditions at a frequency of -0.02% of the clones.
Although melanoma cells are known to be responsive to a-
MSH, their ability to produce this peptide has not been
previously recognised. Our observations are particularly sig-
nificant in the light of recent reports that the addition of a-
MSH to cultured B16 melanoma cells can increase the
metastatic capacity of these tumour lines. The results suggest
that a-MSH may be a key autocrine and possibly paracrine
factor which determines the high degree of invasion and
metastasis that is characteristic of the progression of
melanomas.
Gene amplification, growth factor/receptor genes and
oncogenes are associated with sister chromatid exchange in
melanoma and glioma cell lines
M.S. Lakshmi & G.V. Sherbet
Cancer Research Unit, University of Newcastle upon Tyne,
Medical School, Newcastle upon Tyne NE24HH, UK.
Genetic recombination has been suggested as a mechanism
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tional events, seen as sister chromatid exchanges (SCE),
correlate with metastatic potential of B16 melanomas. Since
unequal homologous SCEs can lead to gene amplification,
we have examined the incidence of SCE and gene amplifica-
tion seen as double minute chromosomes (DM) in Fl (low
metastasis) and BL6 (high metastasis) variants of the B16
murine melanoma.
SCEs occurred predominantly in the hypertriploid cells of
both cell lines. A high proportion of these were also DM
positive. The BL6 line had 2.5 x more DM+ cells than the
Fl line. Hypodiploid cells showed no DMs in spite of high
SCE incidence. In the human glioma GUVW, SCEs and
DMs occurred markedly in hypertriploid cells. We propose
that unequal SCEs occur at gene loci flanked by repetitive
sequences and cause gene amplification. This postulate
assumes that SCEs are a non-random event. The chromo-
somal distribution patterns of SCE were found to be differ-
ent for human melanoma and astrocytoma cell lines. The
SCE break points occurred in the proximity of chromosomal
fragile sites and involved genes for growth factors/growth
factor receptors and oncogenes. Thus, in the melanoma, the
break points involved epidermal growth factor gene, neu, Ki-
ras, myb and ros. In the glioma, Rbl, N-ras and DHFR
genes were involved. In both tumour types, glucocorticoid
receptor gene, P2-microglobulin gene and its regulator gene
were involved.
The isolation of cDNA clones for cysteine proteases and
measurement of the expression of corresponding genes in
metastatic variants of B16 melanoma
J. Lunec, C. Parker & G.V. Sherbet
Cancer Research Unit, The Medical School, University of
Newcastle upon Tyne, Newcastle upon Tyne NE24HH, UK.
Cysteine proteases such as cathepsin B possess a highly
conserved amino acid sequence at the putative active site.
cDNA clones for gene encoding this conserved sequence
have been isolated from a B16 melanoma cDNA library
using the corresponding mixed synthetic oligonucleotide
probe. DNA from one of these clones, designated Agt
lOBL6-CysP-1, has subsequently been used as a probe in
Northern and Southern transfer hybridisation studies to
compare expression of the corresponding gene between B16
melanoma variants showing different capacities for local
invasion and metastasis, and to test for possible rearrange-
ments of the gene or alteration in copy number. Subsequent
restriction mapping has identified Agt lOBL6-CysP-1 as a
cDNA clone for Cathepsin-L.
Three B16 melanoma tumour lines were analysed: B16-Fl,
which only metastasises to the lung at a low level; B16-BL6,
which is selected for increased ability to metastasise to the
lung and penetration of bladder epithelium; and B16-ML8,
which is derived from lung metastases of the B16-BL6
primary, exhibits an even greater ability to metastasise to the
lung but appears to be less locally invasive than either B16-
BL6 or B16-Fl. The Cathepsin-L probe detected a single
1.6 kb transcript in RNA samples from all of these cell lines,
whether grown in culture or as the primary tumour. This
transcript was expressed at an elevated level in the B16-BL6
tumour compared with B16-Fl. No difference was evident
when the cells were grown in culture. However, B16-ML8
was found to express the Cathepsin-L transcript at a greatly
reduced level in cell culture compared with either Bl6-Fl or
B16-BL6. This difference was not so apparent in tumour
samples. These observations suggest that invasion and meta-
stasis are dissociable phenomena and that the expression of
Cathepsin-L may be associated with local invasion but not
metastasis in this system.
Expression df major histocompatibility complex (MHC)
products in colorectal cancer
D.J. Jones' 2, A.K. Ghosh', M. Moore', J.M.T. Howat3
& P.F. Schofield2'
'Department of Immunology, Paterson Institute for Cancer
Research, Christie Hospital, Manchester; 2Department of
Surgery, University Hospital of South Manchester; and
3Department of Surgery, North Manchester General
Hospital, UK.
Lymphocytic infiltration is a favourable prognostic factor in
colorectal cancer. If this phenomenon is tumour antigen
related, MHC expression would be important, since func-
tional T-lymphocyte subsets recognize cell bound 'foreign'
antigen, preferentially in the presence of MHC class I and II
molecules. To test this hypothesis MHC expression was
studied immunohistochemically on cryostat sections of 100
prospective colorectal carcinomas, using monoclonal anti-
bodies to class I and II molecules. Normal mucosa was
studied from 64 cases.
Normal mucosa and 96% of carcinomas were class I
positive. Class II positive epithelia were detected in 13% of
normal sections compared to 57% of carcinomas
(X2=30.47, P<0.001). 11/12 (92%) Dukes' A class II
positive compared to 46/88 (52%) Dukes' B and C
(X2=5.17, P<0.025). MHC expression was independent of
the extent of infiltration.
Class II expression was also observed in 5/5 cases of
inflammatory bowel disease.
The ability of epithelial cells to express class II antigens is
therefore a feature of both non-neoplastic and neoplastic
mucosa, but in carcinomas induction of class II expression is
decreased in advanced disease and could be associated with
escape from immune surveillance. However, since MHC
expression was independent of the extent of lymphocytic
infiltration, the observed in situ immune response is unlikely
to be tumour specific.
Ras oncogene expression in colorectal cancer
D.J. Jones"2, N. Salhabl 2, A. Kinsella', P.F. Schofield2
& M. Moore'
'Paterson Institute for Cancer Research and 2Department of
Surgery, Christie Hospital, Manchester M209BX, UK.
c-Ha-ras and c-Ki-ras gene expression were studied in 31
colorectal carcinomas by Southern blotting and immuno-
histochemical staining of cryostat sections using the monoc-
lonal antibody, Y13-259. Amplification of Ha-ras and Ki-ras
were detected in 11 and 9 tumours respectively (two had
amplification of both genes). Two tumours with low level
amplification also had point mutation at codon 12. Staining
was membrane associated in normal mucosa, but predomi-
nantly cytoplasmic in carcinomas. Staining intensity was
unrelated to the degree of amplification. The abnormal
distribution in carcinomas may be due to perturbed produc-
tion and handling of ras proteins in malignancy. Ras gene
abnormalities were independent of differentiation, Dukes'
stage and DNA ploidy status (determined by flow cyto-
metry), but, there was a significant association between gene
amplification and a previous or family history of colorectal
cancer (Fisher; P=0.013). These preliminary data suggest
gene amplification may identify patients at risk of developing
metachronous tumours and population subgroups for whom
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Modulation of colonic cell phenotype by growth on collagen
gels
J.M. Walling', J.A. Hickman' & S. Townsend2
ICRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET;
and 2MRC Radiobiology Unit, Chilton, Didcot, Oxon
OXJ JORD, UK.
Previous studies on mouse mammary epithelium have shown
that growing cells on floating collagen gels induces the
expression of genes normally associated with the differen-
tiated phenotype (e.g. Lee et al., J. Cell Biol., 98, 146, 1984).
We have studied the effect of collagen gels supplemented
with other extracellular matrix components on the growth of
three mouse colon cell lines in vitro (MAC 13j, MAC 15j,
MAC 26j). These cell lines were newly derived from serially
transplanted adenocarcinomas of the large bowel induced by
prolonged administration of 1,2 dimethylhydrazine (Double
et al., J. Natl Cancer Inst., 54, 271, 1975). Morphologically,
the MAC 15j cell line has the most differentiated phenotype
in vitro. All three cell lines are heterogeneous populations
consisting of both goblet cells and non goblet, possibly
enterocytic cells.
The growth rate of the MAC 13j cell line was independent
of substrate (plastic vs. type 1 collagen gel) whereas growth
of MAC 15j cells was retarded by a collagen substrate. The
major phenotypic effect in these cells when cultured on
collagen was the almost complete loss of goblet cells.
Whether this represents true terminal differentiation of
committed stem cells or simple selection for the enterocyte
type cell remains to be determined. Electron microscopic
examination revealed little change in ultrastructure when
cells were grown on type 1 collagen supplemented with
fibronectin, type IV collagen or laminin.
Laminin inhibits the attachment of glioma cells to type IV
collagen
G. Hunt* & G.V. Sherbet
Cancer Research Unit, University of Newcastle upon Tyne,
Newcastle upon Tyne NEJ 7RU, UK.
Laminin, a basement membrane glycoprotein, is known to
act as an attachment factor for some cell types and thus has
been implicated in the metastatic process. This study has
investigated the effect of laminin on the attachment of
[methyl-3H] thymidine-labelled cells to tissue culture wells
coated with type IV (basement membrane) collagen. The
attachment of the B16 murine melanoma BL6 metastatic
variant was enhanced (P<0.01 by two sample t test), the
attachment of the B16F1 poorly metastatic variant was
unaffected and the attachment of human glioma cell lines G-
IJK, G-UVW and U373MG and rat glioma cell line C6 was
inhibited (fl<0.01, fl<0.01, ,B<0.05 and fl<0.001 respec-
tively, by two sample t test). Laminin appeared to exert its
effect by adsorption to the collagen and was not cytotoxic to
the glioma cells. One of the most unusual features of human
and experimental gliomas is the apparent rarity of spontane-
ous metastasis to extracranial sites. However, the effect of
laminin observed in this study may not be the only factor
determining the metastatic inefficiency of this tumour type.
*Present address: Department of Pathology, University of
Newcastle upon Tyne, UK.
The role of protein kinase C (PKC)) in the growth inhibition
caused by 12,0-tetradecanoylphorbol-13-acetate (TPA) and
related compounds
I.L. Dale & A. Gescher
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
TPA potently inhibits the growth of A549 human lung
carcinoma cells with an IC50 of 0.1 nM (Gescher & Reed,
Cancer Res., 45, 4315, 1985). Mezerein, a tumour promoter
which is structurally related to TPA, induces less potently
the same growth-inhibitory effects as TPA (IC50 4nM) (Dale
& Gescher, Br. J. Cancer., 56, 184, 1986). In the present
study the potential role of PKC in the TPA-induced growth
arrest of A549 cells has been further investigated. It was
found that the synthetic diacylglycerols l-oleoyl-2-
acetylglycerol and 1,2-dioctanoylglycerol were unable to
induce growth arrest at non-toxic concentrations (< 100yM).
Also, the specific PKC inhibitor H-7 at concentrations of up
to 100 pM did not alter growth inhibition induced by 10 nM
TPA. PKC activity and its subcellular distribution were
determined after partial purification by non-denaturing
PAGE. In cultures treated with TPA gross PKC transloca-
tion occurred from the cytosol to the membrane within
30min. Translocation was half-maximal on incubation with
50 nM TPA. On further incubation PKC activity was com-
pletely downregulated within hours. Diacylglycerols did not
induce PKC translocation. PKC translocation caused by
100 nM mezerein was only 25% of that observed with
100 nM TPA. These results suggest that (i) activation of
PKC is insufficient for growth arrest in A549 cells; and (ii)
growth inhibition occurs at concentrations much lower than
that required for gross enzyme translocation.
Concentration-effect modelling for cytotoxic drugs
D.J. Kerr & S.B. Kaye
CRC Department of Medical Oncology, University of
Glasgow, UK.
There are few data relating the activity of cytotoxic drugs in
vitro to their antitumour efficacy in vivo. Usually an arbi-
trary criterion of effect in vitro e.g. the concentration of drug
which induced 50% clonogenic cell kill (ID50) in vivo, such
as the peak plasma concentration of the drug at the host
LD10 dose (i.e. dose which kills 10% of animals). This
allows very limited correlation between model systems of
different complexity and is impractical for predictive ranking
of drug activity. Following detailed pharmacokinetic studies
conducted in nude mice bearing xenografts we have con-
structed a computer model using non-linear least squares
fitting which relates plasma concentration of doxorubicin to
tumour concentration. We used published data to provide
clonogenic cell survival data for MGH-UI cells grown in
vitro (monolayer and spheroid) and in vivo as xenografts.
Log dose response curves for monolayer and spheroid data
was fitted to a Hill-type equation and by combining these
parameters with the pharmacokinetic ones it was possible to
predict clonogenic survival in xenografts from the in vitro
data.
Surviving clonogenic Predicted
fraction (xenograft)
(post treatment) Actual Monolayer Spheroid
2h 0.83 0.74 0.9
18 h 0.76 0.37 0.65230 TWENTY-NINTH ANNUAL MEETING OF THE BRITISH ASSOCIATION FOR CANCER RESEARCH
Clearly the spheroid model is a better predictor of response
in vivo than monolayer and this relates to its three-dimen-
sional configuration and relative drug resistance.
Development and characterisation of cisplatin-resistant
human bladder and testicular tumour cell lines
M.C. Walker & J.R.W. Masters
Institute of Urology, St Paul's Hospital, London WC2, UK.
Cisplatin (CP) is the most active single agent in the treat-
ment of advanced testicular germ cell tumours and transi-
tional cell carcinomas of the bladder. Consequently,
resistance to this drug is an important cause of treatment
failure.
CP-resistant cells were derived in vitro from a human
testicular tumour cell line (SuSa) and a bladder carcinoma
cell line (RTI 12) by continuous exposure to increasing
concentrations of CP. SuSa cells were initially exposed to
50 ngml-1 CP, and after 12 months were able to grow
continuously in 300ngml-1 CP. RT112 cells were initially
exposed to 80 ngml-1 CP and after 15 months were able to
grow continuously in 3.5 igml-1 CP. Comparing IC70s (CP
concentration required to kill 70% of clonogenic cells) (see
Table), SuSa-CP was 6-fold more resistant than SuSa, and
RT112-CP was 4-fold more resistant than RT112. These
levels of resistance were retained when the sublines were
maintained in the absence of CP for 3 months.
The isozyme profiles, population doubling times (PDT)
and plating efficiencies (PE) of parent and resistant cell lines
were studied (see Table). The isozyme studies showed that
the resistant sublines were not cross-contaminated with other
cell lines.
ID70 (ugml-') PDT PE
Cell line I h exposure (h) (%)
RT1l2 5 22 71
RTl 12-CP 20 22 51
SuSa 0.8 31 7
SuSa-CP 5 32 17
Spectrum of differential drug sensitivities in vitro of a
testicular germ cell tumour
C. Xiao" 2 & J.R.W. Masters'
'Urological Oncology Unit, University College, St Paul's
Hospital, London WC2H9AE; and 2Department of Urology,
Tong/i Medical University, Wuhan, PR China.
Testicular germ cell tumours are curable in the majority of
cases using combination chemotherapy, even at advanced
clinical stages of disease. We have shown that continuous
cell lines derived from these tumours are significantly more
sensitive to drugs, including cyclophosphamide, cisplatin and
adriamycin (M.C. Walker et al., J. Natl Cancer Inst., 79,
213, 1987) and gamma-irradiation than bladder cancer cell
lines. In order to identify the mechanism underlying the
differential sensitivity of testicular tumour cells we have now
compared the sensitivities of a continuous cell line derived
from a non-seminomatous testicular germ cell tumour, 833K,
with those of a cell line derived from a transitional cell
carcinoma of the bladder, RT112, to a spectrum of anti-
cancer agents of different classes and mechanisms of action.
These included the alkylating agents chlorambucil and thio-
tepa, the antimetabolites methotrexate and 5-fluorouracil,
the antibiotics bleomycin, mitomycin-c and daunorubicin,
the nitrosoureas CCNU and BCNU, the topoisomerase
inhibitors m-AMSA and VP16, and vincristine and
vinblastine.
Preliminary data indicate that the testicular tumour cells
are more sensitive than the bladder tumour cells to all the
agents tested. Because the spectrum of sensitivity to drugs is
so broad, a possible explanation for the differential sensi-
tivity of testicular tumours is a single common deficit in a
fundamental aspect of DNA repair.
Chemosensitivity to doxorubicin of early passage cells from
breast biopsies
S. Stallard', R.I. Freshney', J.A. Bradley2 & W.D.
George2
'Department of Medical Oncology and 2Department of
Surgery, University of Glasgow, UK.
Little is known about the relative sensitivities of breast
carcinomas and normal breast tissue, although it is often
assumed that tumours are the more sensitive. In this study, a
colony forming assay has been used to examine the relative
sensitivities of breast tumour cells and normal breast epithe-
lial cells to doxorubicin. Paired samples of tumour and of
normal breast were obtained from eleven previously
untreated women undergoing mastectomy. After collagenase
digestion organoids were plated onto plastic, and epithelial
cell outgrowths were maintained in primary culture, where
they grew as ring colonies. The epithelial nature of these cells
was confirmed by morphology, by EM, and by staining with
antibodies to cytokeratin, lactalbumin and HMFG 1 and 2.
After 5 to 7 days proliferating cells were subcultured onto
fibroblast feeder layers and were treated in situ with doxoru-
bicin at a range of concentrations for 24h. Colonies were
then counted after two weeks. The drug concentration
required to kill 50% of the tumour cells varied about
twenty-fold (range 2.7 x 10-8 to 6 x 10-7 M). In all eleven
patients, the dose response curves were similar for tumour
and for normal breast.
These findings suggest that there is marked inter-patient
variation in doxorubicin sensitivity, but that breast tumour
sensitivity is close to that of normal tissue in a single
individual.
In vitro and in vivo responses of a panel of murine colon
tumours to adriamycin: A poor correlation
R.M. Phillips, M.C. Bibby & J.A. Double
Clinical Oncology Unit, University of Bradford, Bradford,
West Yorkshire, BD7JDP, UK.
The present study was undertaken to assess whether or not a
tumour colony forming assay could have retrospectively
predicted the response of a panel of murine colon tumours
(MAC tumours) to adriamycin (ADR). Previous studies in
this laboratory have described the response of two subcuta-
neously grown solid tumours, MAC 13 and 30T to ADR
(Double & Ball, Cancer Chemother. Rep., 59, 1083, 1975;
Double & Bibby, Br. J. Cancer, 48, 739, 1983). Both
tumours are resistant to a single bolus injection of ADR
(1Omg Kg - i.p.). In this study, MAC 15A tumours grown
either as an ascites or systemically as small 'spheroid like'
lung nodules demonstrated only partial sensitivity to ADR
(10mgkg-1, i.p. and i.v.). The inherent chemosensitivity of
cell lines derived from these tumours was assessed using a
modified clonogenic assay (Bibby et al., Br. J. Cancer, 55,
1987) at therapeutically relevant drug exposures. Increasing
the duration of drug exposure resulted in increased cyto-
toxicity for all the time points studied suggesting that
improved anti-tumour effects in vivo may be achieved if
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scheduling'. In all the cell lines tested, significant reductions
in colony formation (>90%) were observed in vitro under
time and concentration conditions that approximate plasma
and peritoneal C x t values for ADR in non-tumour bearing
NMRI mice following i.p. and i.v. bolus injections of ADR
(10mgkg-1). On the basis of these findings, good responses
in vivo would be predicted. The poor correlation that exists
between in vivo responses to ADR and in vitro chemo-
sensitivity as assessed by a clonogenic assay, suggest that
other factors, possibly related to the three-dimensional struc-
ture of solid tumours, have a significant influence on the
final outcome of chemotherapy in this model.
Characterization of a tetrazolium based chemosensitivity
assay suitable for non-adherent small-cell lung cancer cell
lines
J.A. Plumb, R. Milroy & S.B. Kaye
Department of Medical Oncology, University of Glasgow,
Glasgow GJ29LX, UK.
Development of drug resistance is common in small-cell lung
cancer. However, studies of drug resistance in vitro with
small-cell lung cancer (SCLC) cell lines present major
problems. The cell lines are frequently non-adherent and
grow as floating aggregates which do not disrupt into viable
single cell suspensions. Hence standard chemosensitivity
assays are not suitable. Those used often rely on disruption
of the aggregate and hence a decrease in cell viability prior
to drug exposure. We have characterised and modified a
chemosensitivity assay based on the reduction of a tetrazo-
lium dye, MTT, by live but not dead cells. For adherent cells
this assay correlates well with a standard clonogenic assay,
provided that sufficient MTT is used and the pH is
controlled. We have now validated this assay for use with
non-adherent small-cell lung cancer cell lines. Frozen
sections of SCLC cell aggregates incubated in MTT contain
MTT-formazan crystals throughout the viable cell popula-
tion. Furthermore, we have also shown by fluorescent mic-
roscopy of frozen sections that adriamycin is able to
penetrate throughout this same cell population. This con-
trasts with our observations of limited penetration of adria-
mycin in spheroids prepared from mono-layer cell lines.
Thus, all cells in the SCLC aggregates are exposed to drug
and MTT reduction can be used as an estimate of total cell
numbers without the need to disrupt the aggregate. We have
used MTT-formazan production to measure both the growth
rates and chemosensitivities of a number of newly estab-
lished cell lines.
The MTT assay underestimates growth inhibition by
interferons in human lung cancer cells
S.A.B. Rashid, P.R. Twentyman & J.V. Watson
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB22QH, UK.
The growth inhibitory effects of recombinant interferons
(IFNs) x and y on human lung cancer cell lines was studied
using both a tetrazolium (MTT) colorimetric assay and
direct cell counting. Significant discrepancies between the
two assays were observed (see table below).
Cell lines % Inhibition of cell growth of controls
a IFNatIkUml-U yIFNatJkUml-1
MTT Cell count MTT Cell count
'Classic' (NCI-H69 10-20 20-40 10-15 20-30
small POC 10-20 50-60 20 60-80
cell COR-L88 30 70-80 10-15 10
Large cell COR-L23 10-20 20 30 75-85
There is no direct chemical effect of IFNs on the tetrazolium
reduction process. IFN treated cells showed increased cell
size (Coulter) compared with control cells, although there
was little or no change in cell cycle distribution. Mitochon-
drial activity (the basis of formazan production) was 30%
greater in y IFN treated cells (COR-L23) than the controls.
Reduced formazan production/cell was observed in medium
which had supported cell growth for several days. Differen-
tial 'medium conditioning' led to a difference in formazan
production/cell between IFN and control cells and this was
the major basis of the observed discrepancy.
Small cell lung cancer: Alteration of tumour cell phenotype
in vitro and its effect on chemosensitivity
A.M.B. Murray & R.I. Freshney
Department of Medical Oncology, University of Glasgow,
Glasgow, UK.
Elevated levels of L-DOPA decarboxylase (DDC) and crea-
tine kinase BB (CKBB) have been shown to be characteristic
of a number of small cell lung cancer (SCLC) cell lines.
These two properties have been selected to represent the
SCLC phenotype. The aim of this study was to determine
whether the SCLC phenotype can be altered by drugs known
to induce phenotypic changes in other cell lines.
Cells in log phase were exposed to drug for 72 h, harvested
and their DDC and CKBB activities determined. DDC
activity was determined from the rate of formation of 3H-
dopamine from 3H-DOPA, and CKBB activity by a NAD
linked enzymatic method and characterised by electrophore-
tic analysis.
HMBA (1.0mM) reduced the DDC activity in both NCI-
H187 (P<0.05) and NCI-H69 (P<0.01), and increased the
CKBB activity in H69 (P<0.05). Moreover, sodium butyrate
(0.1 mM) reduced the DDC levels in the three lines examined,
H187 (P<0.01), H69 (P<0.001) and NCI-HI28d (P<0.02),
and increased the CKBB levels in H187 (P<0.01) and H69
(P<0.05). Similarly, dibutyryl cAMP (0.5mM) was also
found to reduce the DDC activity in H69 (P<0.05), and
increase the CKBB levels (P<0.05). All drug concentrations
used were non-cytotoxic.
These results suggest that the SCLC phenotype can be
altered by drug treatment. We have investigated whether
these phenotypic changes affect the chemosensitivity of the
cells. A chemosensitivity assay was used based on the
reduction of a tetrazolium dye. The adriamycin ID50 was
found to be 3.51 X 10-8 M for H187, 4.37 x10-8 M for H69
and 7.5 x 10-8 M for H128d. However, the effect of the
above drug induced changes on the chemosensitivity of the
cell lines is as yet unclear.
Actions of a progestogen on the efficacy of cytotoxic drugs
N.A. Shaikh', K. Patel2, A.M. Owen2, M.W. Ghilchik1 &
H. Braunsberg2
'Breast Clinic and 2Chemical Pathology Department,
St Mary's Hospital and Medical School, London W2 IPG,
UK.
The use of hormones to enhance the effects of cytotoxic
drugs has met with partial success, but exploration of this
approach has not yet been exhausted. We have achieved very
promising clinical results by sequential administration of
oestradiol (E2), medroxyprogesterone acetate (MPA) and
cytotoxic drugs and have now attempted to validate this
therapy by in vitro experiments with cultured human breast
cancer cells (MCF-7).
Cells, grown in the presence of dextran-charcoal stripped
foetal calf serum for 3 days, were treated with or without
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medium. The washed monolayers were grown for a further 3
days with medium containing untreated FCS and cell yields
estimated. Hormone-drug interactions were assessed by Stu-
dent's t tests, analysis of variance and estimation of apparent
doubling times.
MPA (10-80nM) significantly affected the efficacy of
methotrexate (MTX) and vincristine (VCR) at concen-
trations (10 and 0.1 nM, respectively) at which the drugs
alone gave a barely detectable decrease in cell yields. The in
vitro effects of sequential oestradiol/MPA treatment and
those of MPA on the action of other drugs used in our
regimen are under investigation.
The enhancement of the action of cytotoxic drugs through
pretreatment with MPA, now also demonstrated in vitro,
deserves more extensive clinical trials.
Survival studies in Chinese hamster ovary cells following
drug or radiation exposure using the cytochalasin assay in
comparison to a clonogenic method
J.B. Court, C. Burn & J.L. Moore
Radiation Sciences Laboratory, Velindre Hospital, Cardiff
CF4 7XL, Wales, UK.
We have developed (Court & Moore, Cell. Biol. Int. Rep., 9,
219, 1985) an assay for Chinese hamster ovary cell viability
that is based on the ability to multinucleate in the presence
of the fungal metabolite cytochalasin B (CB) following expo-
sure to radiation or to cytotoxic drugs. The degree of
multinucleation achieved is assessed after a given incubation
period in CB by measurement of the cellular DNA content
using the flow cytometer. The method is intended to permit
estimation of the survival of DNA synthesis in situations
where cells cannot be fully monodispersed.
Cells were seeded from the same stock culture at either
400 cell/flask for conventional clonogenicity studies, or at
1 x 10E6 cell/flask for the estimation of the DNA content
following incubation in CB. All cultures were exposed to the
same cytotoxic drug solution, or to 137-Cs gamma irradia-
tion either at a high dose-rate of 0.5 Gymin 1, or at a low
dose-rate of about 1 cGymin-1.
Radiation survival curves after single doses up to 20Gy
are exponential, with no evidence for a threshold in the
survival of the ability to reach a DNA content of at least
3 x GI in the presence of CB. We have investigated the
relationship between this apparent lack of repair of sublethal
damage in the multinucleation system to the change in
survival curve slope at low dose rates. Comparisons have
also been made between the survival of clonogenic potential
and the survival of DNA synthesis, in CHO cells exposed to
cisplatinum, Novantrone, cytosine arabinoside, 5-
fluorouracil, or vinblastine, all as single agents.
Cytotoxicity of fatty acids on normal and malignant cells in
vitro
B. Fermorl, N.A. Habib', J.R.W. Masters2, J.C. Coffey2,
C.B. Wood3 & R.C.N. Williamson3
'Department of Surgery, Bristol Royal Infirmary; 2Institute
of Urology, London; 3Department of Surgery, RPMS,
London, UK.
The membranes of malignant cells showed increased oleic
acid in relation to stearic acid content in comparison with
their normal counterparts (Wood et al., Eur. J. Onc., 11,
347, 1985). The cytotoxic effects of saturated stearic, mono-
unsaturated oleic and dihydroxystearic acids on two testicu-
lar tumour (SuSa, 833K), two bladder carcinoma (RT112,
RT4), one colorectal tumour (HT29), one normal urothelium
(HU609) and one normal fibroblast (HFL) cell lines were
measured using a colony forming assay. Stearic acid was up
to five times more cytotoxic than oleic acid.
IC 50ugm-1 (mean+s.e.m.)
Tumour Cell line Stearic acid Oleic acid
Testis SuSa 2.8+1.4 16.5+2.3
833K 5.0+0.2 26.6+2.5
Bladder RTI12 4.4+0.8 22.4+3.0
RT4 7.6+0.4 25.0+0.7
Colon HT29 7.6+0.2 34.3+0.8
Fibroblasts HFL 8.7+0.1 21.8+0.7
All tumour cell lines with the exception of RT4 were more
sensitive to stearic acid than the normal fibroblasts
(<0.001 <P<0.05). However the well differentiated bladder
tumour, RT4 was more sensitive than normal fibroblasts to
oleic acids (P<0.05). It was also found that the 3 tumour
cell lines tested were more sensitive than the normal urothel-
ium and fibroblasts to dihydroxystearic acid (data not
shown). Our data suggest that the stearic acid is more
cytotoxic to tumour cells than oleic acid, and that this may
be related to the higher proportion of oleic acid in the
tumour cell membranes.
Thermochemotherapy with melphalan and human melanoma
spheroids
R.N. Scott, T.E. Wheldon, S.B. Kaye, R.M. MacKie &
A.J. McKay
Departments of Surgery and Oncology, Gartnavel General
Hospital; Radiobiology Group, Belvidere Hospital; and
Department of Dermatology, Western Infirmary, Glasgow,
UK.
Isolated limb perfusion (ILP) is the most effective treatment
for loco-regional recurrence of melanoma. The value of
hyperthermia during ILP with melphalan is controversial.
Both ILP and the multicellular tumour spheroid (MTS)
model allow the manipulation of tumour microenvironments
outwith normal physio-pharmacological ranges. The MTS
model is thus a useful analogy for conditions during ILP.
The aim of this work was to study the effect of tempera-
ture on the cytotoxic effect of melphalan using human
melanoma MTS.
We have grown MTS from several established cell lines.
MTS of the B8 line were exposed to clinically achieved
concentrations of melphalan for 1 h at temperatures from 31
to 44.5°C. Spheroid volume was measured subsequently to
obtain growth curves. Spheroids were also disaggregated for
clonogenic assay.
Using regrowth delay and clonogenicity of disaggregated
spheroids our results show that, despite the increased rate of
hydrolysis of melphalan at higher temperatures, the cytotoxic
effect of the drug is enhanced by heat. At hypothermic
temperatures there was no significant difference in cytotoxic
effect compared with normothermia.
These results support the use of hyperthermia during ILP
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Mutation and drug resistance in human tumour cell lines in
vitro
C.N. Parris & J.R.W. Masters
Institute of Urology, St Paul's Hospital, London
WC2H9AE, UK.
Testicular germ cell tumours are curable in advanced stages
using chemotherapy, unlike most other types of cancer. Drug
resistance in all forms of cancer may develop as a result of
mutation induced by chemotherapy. The spontaneous and
induced mutation frequencies (MF) in cell lines derived from
three testicular (SuSa, 833K, GH) and two bladder (RTl 12,
RT4) tumours were compared. In addition MF were com-
pared also in a testicular and bladder subline made resistant
to the drug cisplatin (SuSa-CP, RTl 12-CP). Hypoxanthine
guanine phosphoribosyl transferase (HGPRT) locus muta-
tions were selected by resistance to 10 jugml- 6 thioguanine.
Induced mutation frequencies were compared following
exposure to a range of concentrations of the mutagen ethyl
methane sulphonate (EMS) (see Table).
MF at 0.6mgml- I
Cell type Line Spontaneous MF EMS
Bladder RT112 2.5 x 10-5 3.1 x 1O-5
Bladder RT112-CP 1.8 x 10-5 2.2 x 10-5
Bladder RT4 4.4x 10-6 5.6x 10-6
Testis SuSa 6.9 x 10-6 1.1 x 10-5
Testis SuSa-CP 5.2x 10-6 2.2x 10-5
Testis 833K 5.8 x 10-6 2.2 x 10-5
Testis GH 1.5 x 10-6 8.0 x 10-6
Within the bladder and testicular cell lines there is overlap
of both spontaneous and induced MF. In the cell lines made
resistant to cisplatin there is no significant change in MF. In
these cell lines there is no association between drug sensitiv-
ity or resistance and mutation frequencies.
Elevation of H{L-60 cell intracellular calcium by the
cytotoxic ether Upid SRI62-834 and antagonism by 12-0-
tetradecanoyl-phorbol-13-acetate
vented by the protein kinase C-activating phorbol ester, 12-
0-tetra - decanoyl - phorbol - 13 - acetate (TPA). After a
10 min preincubation with 3 nM TPA, the calcium rise
induced by 30,uM SRI 62-834 was 50% inhibited, and
lOOnM TPA completely abolished it. This suggests that the
elevation of intracellular calcium mediated by SRI 62-834 is
possibly the result of the opening of a calcium channel, the
activity of which is regulated by protein kinase C.
In vivo-induced resistance to chloroethylating agents
correlates with increased O(-alkylguanine DNA
alkyltransferase expression in a murine solid tumour
P. Workman1, K.L. Kooistra1, F.Y.F. Lee1, J. Donaldson1
& G.P. Margison2
1MRC Clinical Oncology Unit, Cambridge; and
2Department of Carcinogenesis, Paterson Institute,
Manchester, UK.
Sensitivity of mammalian cell lines to chloroethylating agents
is associated with low expression of the repair protein 06_
alkylguanine DNA alkyl(transferase (ATase). This removes
the chloroethyl monoadduct DNA from the 06 position of
guanine, thus preventing potentially lethal DNA crosslink
formation. However, it is still not clear at this time to what
extent de novo and acquired resistance to chloroethylating
agents are associated with increased expression of ATase in
solid tumours. The KHT sarcoma of C3H mice is highly
sensitive to chloroethylating agents. By serial in vivo treat-
ment with CCNU or mitozolomide and retransplantation,
we produced two sublines (KHT/CCNU and KHT/mitozol)
with stable resistance to these agents: e.g., CCNU, BCNU,
mitozolomide and clomesome produce growth delays of 0-4
days, compared to 20-30 days with some cures for the
parent tumour. ATase activity was assayed by the transfer of
radioactivity from 3H-methylnitrosourea-methylated calf
thymus DNA. The levels (±2s.e.) in fmol/mg protein were:
parent KHT 19.0+6.0; KHT/CCNU 53.2+12.6, KHT/
mitozol 73.7+5.3 (both P<0.001). We conclude that in vivo-
induced resistance of the KHT tumour to chloroethylating
agents is associated with a 3-4 fold increase in ATase
activity, thus supporting a role for up-regulation of ATase
gene expression as a molecular mechanism of resistance.
M.G. Thompson & J.A. Hickman
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
SRI 62-834 ((±) - 2 - [hydroxy[tetrahydro - 2
(octadecycloxy)methylfuran - 2 - yl] - methoxy]phosphiny-
loxy - N, N, N - trimethylethaniminium hydroxide) is a
tetrahydrofuran analog of the antitumour ether lyso-
phospholipid Et-18-OCH3(l - 0 - octadecyl - 2 - 0 - methyl -
rac - glycero - 3 - phosphocholine). The cytotoxic and
differentiation-promoting activity of the ether phospholipids,
such as Et-18-OCH3, is considered to be mediated either via
direct effects, and/or indirectly by the activation of cytotoxic
macrophages. The direct cytotoxicity has been suggested to
be the result of the inhibition of normal phospholipid
metabolism and the subsequent perturbation of membrane
function. In view of this, we have investigated the activity of
SRI 62-834 on the calcium homeostasis of HL-60 human
promyelocytic leukaemia cells, and find it rapidly to elevate
intracellular calcium concentrations in a concentration-
dependent manner, as monitored by the calcium indicator,
Quin-2. In a typical experiment, 30pM SRI 62-834 elevated
the concentration of intracellular calcium from a resting
level of 179 nM to 445 nM/1.5 x 10 cells. This was partially
inhibited by preincubation with the voltage-dependent
calcium-channel blocker, verapamil, and completely pre-
Changes in cellular glutathione and glutathione-S-transferase
levels associated with resistance to L-phenylalanine mustard
(melphalan)
R.A. Britten & J.A. Green
CRC Department of Radiation Oncology, University of
Liverpool, Clatterbridge Hospital, Bebington, Wirral
L634JY, UK.
Cellular glutathione plays an important role in the modula-
tion of alkylating agent cytotoxicity. The relationship
between cellular glutathione transferase (GSH-TFR), GSH
and GSSG levels and alkylating agent resistance has been
studied in the human ovarian OAW42 cell line. The effect of
oxothiazolidine-4-carboxylate (OTZ) and buthionine sulfoxi-
mine (BSO) has also been determined. The melphalan-
resistant subline OAW42/MER was developed by step-wise
incubation with the drug, and found to be 4-fold more
resistant to melphalan than the parent OAW42 line. Total
glutathione and GSH-TFR activity were 1.5 fold greater in
OAW42/MER than in OAW42. The GSSG/GSH-TFR ratio
was 0.11 in OAW42, and 0.25 in OAW42/MER. The
difference in glutathione levels was therefore attributed to an
elevation in GSSG content of OAW42/MER. 50 uM BSO
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both cell lines, and reduced total glutathione to 78.6% and
40.3% of control values respectively in OAW42 and
OAW42/MER. The level of GSSG was unchanged in
OAW42 but fell to 8.6% in OAW42/MER. GSH-TFR
activity decreased to 64% of control levels in both cell lines.
The GSSG/GSH-TFR ratio remained at 0.11 in OAW42
cells, but fell to 0.08 in OAW42/MER.
Exposure to 50,uM OTZ for 18 h reduced melphalan
cytotoxicity by 5-fold, and significantly increased the GSSG/
GSH-TFR ratio in OAW42 to 0.20. Total glutathione levels
were not altered, but the GSSG/GSH ratio increased by 2
fold. These results suggest a correlation between the propor-
tion of total glutathione in the oxidized form GSSG, GSH-
TFR activity and the degree of resistance to melphalan.
Drug sensitivity in tumour cell lines with different
glutathione transferase content: Dramatic over expression of
enzyme levels in cell lines resistant to 1-chloro-2,4-
dinitrobenzene
C.J. Wareing1' 2, A.D. Lewis2, J.D. Hayes1 & C.R. Wolf2
1Department of Clinical Chemistry, Royal Infirmary,
Edinburgh EH3; and 2ICRF Laboratory of Molecular
Pharmacology and Drug Metabolism, Hugh Robson
Building, George Square, Edinburgh EH89XD, UK.
The glutathione-S-transferases (GSTs) are a multigene family
of enzymes which play a role in many cellular detoxification
reactions. Evidence is emerging that these enzymes also play
a role in the development of resistance to cytotoxic drugs
and anti-neoplastic agents. We are studying the relationship
between GST expression in human tumour cell lines and
their susceptibility to these compounds. The MCF7 cell line
which contains essentially no GST was much more sensitive
than the cell line HT29 to the toxic effects of GST substrates
and chlorambucil. In an alternative approach we have made
a human lung tumour cell line (NCI H322) resistant to the
GST substrate CDNB. The resistant line demonstrates
dramatic over expression of GST activity (24 fold), to levels
higher than any normal human tissue, including the liver.
Elevation in both the acidic and basic subunits accompanied
this change. The basic subunit being elevated greater than
100 fold in the resistant line.
Pre-treatment of cells with verapamil enhances the effects of
verapamil on chemosensitivity in vitro
J. Plumb & S.B. Kaye
Department of Medical Oncology, University of Glasgow,
Glasgow GJ29LX, UK.
The calcium antagonist verapamil has been shown to
increase the sensitivity of a number of cell lines to cytotoxic
drugs in vitro and it has been suggested that it may be of
value in attempts to overcome drug resistance in patients.
Although verapamil (6.6pM) increased the sensitivity of a
number of non-small-cell lung cancer (NSCLC) cell lines to
adriamycin, this effect was not observed if verapamil was
added to the cells subsequent to addition of adriamycin. This
suggested that verapamil is not active if the cells have
already been exposed to the cytotoxic drug. We have,
therefore, determined the effects of pre-treatment of cells
with verapamil prior to exposure to adriamycin.
Chemosensitivity was determined by an assay based on the
reduction of a tetrazolium dye, MTT, by live but not dead
cells. Cells were plated in 96 well plates and exposed to
adriamycin for 24 h. For the NSCLC cell line WIL the ID50
for adriamycin alone was 3.0 x 108 M. This was reduced 5-
fold by exposure to adriamycin for 24h in the presence of
verapamil (6.6gM). However, when cells were incubated for
24h in the presence of verapamil (6.6gM) prior to addition
of adriamycin and verapamil, the ID50 was reduced by 20-
fold. In contrast addition of verapamil for 24h after expo-
sure to adriamycin and verapamil did not further reduce the
sensitivity of the cell line. Furthermore, pre-incubation with
verapamil for 24h prior to exposure to adriamycin alone
had no effect on the chemosensitivity. Although the mecha-
nism of action of verapamil in this context is not known the
results suggest that it involves effects on the cell both before
and during drug exposure.
Resistance modifiers verapamil and cyclosporin A:
Differential effects on the chemosensitivity and cellular
pharmacology of anthracyclines in multidrug resistant cells
H.M. Coley, P.R. Twentyman & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge, UK.
Verapamil (VRP) and cyclosporin A (CYA) are under
evaluation for their ability to overcome multidrug resistance.
Using H69 human small cell lung cancer cells, EMT6 mouse
mammary tumour cells and their adriamycin (ADM) resis-
tant counterparts (in vitro derived) we examined the effects
of these agents on chemosensitivity and drug uptake. Che-
mosensitivity testing involved a tetrazolium (MTT) reduction
assay with continuous drug exposure. From a range of
anthracycline analogues tested we selected three drugs, acla-
cinomycin A (ACL), Ro 31-1215, both 9-alkyl derivatives,
and 4'-deoxy-4'-iodo doxorubicin (4'-Jodo), a 4'-daunosamine
derivative, on the basis of their minimal cross-resistance in
the ADM resistant cell lines. Resistance factors (RF=ID50
resistant line/parent line) for H69 and EMT6 respectively
were 225 and 34 for ADM, 5.8 and 4.7 for ACL, 12.4 and
8.1 for Ro 31-1215 and 18.9 and 4.4 for 4'-Jodo. At clinically
comparable concentrations CYA (5 pgml-1) was more effec-
tive than VRP (3.3 pgml-1) in modifying resistance to ADM
and all 3 analogues. In EMT6 with ADM, VRP enhanced
sensitivity more in the parent line (4-14 fold) than in the
resistant line (2-6 fold), whereas the opposite was seen with
the 3 analogues. For H69, enhancement was confined to the
resistant line. CYA increased chemosensitivity in both resis-
tant lines more than in the parent lines for all 4 agents. Drug
accumulation was enhanced in resistant lines to similar
extents by VRP and CYA. Levels achieved approached those
in the parent lines for ADM, Ro 31-1215 and 4'-Jodo,
whereas a negligible effect was seen for ACL. These results
indicate the complexity of resistance modification by agents
of this type.
Modification of cytotoxic drug resistance by non-
immunosuppressive cyclosporins
P.R. Twentyman1 & D.J.G. White2
1MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB22QH; and 2Department of Surgery,
University of Cambridge, UK.
We have previously shown (Twentyman et al., Br. J. Cancer,
56, 55, 1987) that the immunosuppressive agent cyclo-
sporin A (CYA) is an effective modifier of resistance to
adriamycin (ADM) and vincristine (VCR) in the multidrug
resistant variant (LX4) of the human cell lung cancer cell
line NCI-H69. Three naturally-occurring analogues of CYA
were also examined and we found that their ability as
resistance modifiers (RMs) correlated with their immuno-
suppressive properties.
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minimally-immunosuppressive analogues of CYA, either syn-
thetic or derived from naturally-occurring compounds.
Several of these have been found to be highly effective RMs.
Furthermore, two compounds, B3-243 and W8-032 main-
tained good activity in the dose-range 1-2 igml-1 (sensitisa-
tion of LX4 cells to ADM at 2 igml-1= 53 and 32 fold
respectively), whereas sensitisation to ADM by CYA falls
from 50 fold at 5 gml to 10 fold at 21ugml-1.
Preliminary experiments in mice have indicated that B3-
243 can be administered in 5 daily doses of
100mgkg-1day-1 without acute toxicity. Such a schedule
results in blood levels in the range 1-2 jugml-1, i.e. similar to
those which produce effective resistance modification in vitro.
Experiments combining B3-243 and ADM in mice bearing
ADM sensitive and resistant tumours are in progress.
The effects of soluble factors produced by myeloma cells on
bone-derived cells in vitro
C. Evans', C. Ward & C.S.B. Galasko
Department of Orthopaedic Surgery, CSB, Hope Hospital,
Salford M68HD, UK.
Invasion of bone by tumours usually involves osteolysis as
well as some osteogenesis. Multiple myeloma is unusual in
that only osteolysis occurs in the vast majority. To examine
the effect of myelomata on osteogenesis, the myeloma cell
line GM 1500 was co-cultured with human bone-derived cells
(BDC). The BDC were also cultured in medium conditioned
by the myeloma cells (MCM). BDC proliferation was mea-
sured by cell count and DNA synthesis by tritiated thymi-
dine uptake (3H-TdR) assay. Both cell proliferation and
DNA synthesis were inhibited by MCM (by 31% and 41%
respectively). Proliferation of BDC co-cultured with mye-
loma cells was also inhibited (26%). This inhibitory effect
was dependent upon myeloma cell density in the condition-
ing medium. Preliminary work showed that this effect is dose
dependent, and that the active component has a molecular
weight of less than 50,000 daltons. The usual response of
bone to injury (including tumour invasion) is osteogenesis.
The results of this pilot study suggest that myeloma inhibits
this reaction by the secretion of a soluble osteoblast inhibit-
ing factor.
The rate of passage of cells across the restriction point
D.L. Dewey
Cancer Research Campaign, Gray Laboratory, Mount
Vernon Hospital, Northwood, Middlesex HA62RN, UK.
A large number of genetic markers of events in the mamma-
lian cell cycle are already known. Many are concerned with
growth factors and other initiators, but after initiation there
is a long gap of many hours before the start of DNA
synthesis (S). There is no clear indication of what is happen-
ing during this gap except for a point of no return, after
which removing all initiating substances will no longer stop
cells from completing a round of DNA synthesis. This point
in time, usually called the restriction point, is difficult to
measure accurately because the cells that continue to enter S
after removal of these serum factors do so at a reduced rate.
We have found that a low dose of ionizing radiation will not
delay cells which have passed the restriction point but will
induce a dose related delay in cells which have not reached
this point. Moreover, after the delay cells still entered S at
the same rate as unirradiated controls. When a culture was
irradiated in the middle of the restriction point, half of the
cells were delayed and half not. An automatic device for
measuring entry into S has been used to plot these double S
peaks and by irradiating at frequent intervals it has been
possible to measure the rate of passage of a population of
cells across the restriction point.
Inhibitors of DNA synthesis act after the restriction point
and after removal of the inhibitor, DNA synthesis starts
immediately in both irradiated and control cultures. How-
ever a latent delay still existed and could be observed in the
following cycle.
31P NMR spectral changes in in vitro HT29 human colonic
adenocarcinoma cells subjected to hypoxia and photon and
neutron irradiation
S. Myint & H.M. Warenius
Substance P antagonists block the mitogenic effects of the
neuropeptides bombesin, vasopressin and bradykinin in Swiss
3T3 cells
P.J. Woll & E. Rozengurt
Growth Regulation Laboratory, Imperial Cancer Research
Fund, Lincoln's Inn Fields, London WC2A 3PX, UK.
The neuropeptides bombesin and vasopressin have pre-
viously been shown to be mitogens for Swiss 3T3 cells. We
now show that bradykinin is mitogenic for these cells in the
presence of insulin. Its effects are dose-dependent and maxi-
mal at lOnM. Addition of bradykinin to the cells causes an
immediate and transient increase in the intracellular Ca2 +
concentration. DNA synthesis commences at 24 h and is
maximal by 40 h. All these effects are competitively and
reversibly blocked by the substance P antagonists [DArg1,
DPro2, DTrp7 9, Leu"1] substance P at 100juM and [DArg1,
DPhe5, DTrp7 9, LeuP1] substance P at 20pM. These anta-
gonists also selectively antagonise the effects of bombesin
and vasopressin in these cells, although the three peptides
interact with distinct receptors. We suggest that the sub-
stance P antagonist family interacts with a highly conserved
common domain of these receptors.
University of Liverpool Department of Radiation Oncology,
Clatterbridge Hospital, Wirral, Merseyside L634JY, UK.
The application of NMR spectroscopy to the study of living
cells provides a valuable method for the non-invasive moni-
toring of cell energetics and ionic content.
We have used 31p NMR to study metabolic changes
related to hypoxia in cultured HT29 human colon carcinoma
cells in vitro and characterised the 3'PNMR spectrum in
monitoring changes occurring during recovery from hypoxia.
Phosphate metabolites were monitored with time as the
environment in the NMR tube became increasingly hypoxic
for the sedimented cell pellet. Considerable changes in the
levels of these metabolites were observed. These changes are
comparable with those observed in vivo tumour with disap-
pearance of phosphocreatine and glycerophosphorylcholine
and concomitant increase in inorganic phosphate and are
almost completely reversed following reversal of hypoxia by
resuspension and reoxygenation in fresh medium. This tech-
nique when used to compare cells irradiated by photons or
neutrons to controls resulted in different patterns of recovery
following irradiation which showed dose response effects.
These investigations suggest a potential for NMR spectro-
scopy as an early in situ method of studying the response of
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The effects of temperature on post-irradiation recovery in
two human tumour cell lines
J.H. Peacock, A.M. Cassoni, J.J. Eady & T.J. McMillan
Institute of Cancer Research, Sutton, Surrey, UK.
The effect of post-irradiation temperature on cellular reco-
very after exposure to ionizing radiation has been investi-
gated in two human cell lines. One of the lines MGH-Ul,
showed a reduced shoulder to the radiation dose survival
curve when incubated at 25°C for 4h following treatment,
whereas incubation at 0°C for a similar period had no effect.
The other line RT112 was unaffected by either post-
irradiation temperature.
Split dose experiments showed that recovery from sub-
lethal damage is inhibited during the 4h at 0°C and 25°C in
both lines. When returned to 37°C after these incubations
however, RT112 goes on to recover as normal. In contrast,
MGH-Ul cells only recover at 37°C when the previous
incubation was at 0°C not 25'C.
These results suggest that competing processes of radiation
induced damage fixation and repair proceed at 37°C follow-
ing irradiation and in MGH-Ul cells incubation at 25°C
prevents repair but not fixation whereas at 0°C both pro-
cesses are inhibited.
Improved fluorescein-based substrates for flow cytometric
measurement of cellular esterases can be used in combination
with propidium iodide (PI) in a multiparametric assay of cell
viability and membrane permeability
Foetal-like fibroblasts in cancer patients and their potential
role in disease pathogenesis
S.L. Schorl, A.-M. Grey', A.M. Schor2 & G. Rushton2
'Department of Cell and Structural Biology, University of
Manchester; and 2CRC Department of Medical Oncology,
Manchester, UK.
Fibroblasts from breast cancer patients commonly display
certain foetal-like phenotype characteristics. On the basis of
these observations, we have suggested that (a) normal foetal-
to-adult transitions in fibroblast phenotype do not occur in
certain individuals, and (b) the persistence of foetal-like
fibroblasts in the adult puts the affected individual at an
elevated risk of developing breast cancer by virtue of a
dysfunction in normal epithelial-mesenchymal interactions
(Schor et al., Exp. Cell Biol., 55, 11, 1987). We now report
that foetal fibroblasts and the foetal-like fibroblasts of
cancer patients produce a 55 kD migration stimulating factor
(MSF) that is not produced by normal adult fibroblasts, but
induces these cells to display a foetal-like migratory pheno-
type. Foetal fibroblasts undergo a spontaneous transition in
vitro to expression of a characteristically adult migratory
phenotype: this transition is accompanied by a cessation in
the production of MSF. In contrast, the foetal-like fibro-
blasts of breast cancer patients do not undergo this transi-
tion and continue to produce MSF until senescense. The
primary effect of MSF appears to be a stimulation of
glycosaminoglycan (GAG) biosynthesis. We suggest that
perturbations in the control of GAG biosynthesis in vivo
may contribute to tumour progression via their well-
documented effects on angiogenesis, cell proliferation, differ-
entiation and migration.
C. Dive, P. Workman & J.V. Watson
MRC Clinical Oncology Unit, Hills Road, Cambridge
CB22QH, UK.
Fluorescein diacetate (FDA) is widely used to measure cell
viability, membrane permeability and esterase activity. How-
ever, employed as a substrate probe for flow cytoenzymology
(FCE) it is limited by rapid efflux of the product fluorescein
(F). We have therefore evaluated two potentially improved
esterase substrates, carboxyfluorescein diacetate (CFDA) and
bis(carboxyethyl) - carboxy - fluorescein - tetra acetoxy
methyl ester (BCECF-AM) in terms of reaction and product
efflux kinetics. Substrate hydrolysis rates for EMT6 mouse
mammary tumour cells were in the order FDA<<BCECF-
AM> CFDA. The latter had disadvantages of substantial
substrate fluorescence, poor cell uptake and complex kine-
tics, apparently due to participating membrane-bound ester-
ases. In contrast BCECF-AM gave negligible substrate
fluorescence and superior membrane permeability. As pre-
dicted, product efflux slowed markedly with increased pro-
duct polarity. Efflux t1/2s for the products of FDA and
CFDA hydrolysis were 16 and 94min respectively. No loss
of BCEF-AM product (BCECF) was seen after 2h. Thus
BCEF-AM was optimal for FCE. It was subsequently
employed in combination with PI in a multiparametric assay
of cell viability and membrane permeability. The flow cyt-
ometer triggered on light scatter (measuring cell size) and
recorded green (BCECF) and red fluorescence (PI). As
expected viable cells exhibited green but not red fluorescence
while non-viable cells showed the reverse. Interestingly, a
third population (- 4% of cells) showed little green or red
fluorescence. This use of two reporter molecules may provide
more detailed information on the relationship between cell
viability and membrane permeability.
Expression of cytochrome P450 cDNAs in yeast
S. Black" 2, R.R. Meehan" 2, J.D. Beggs3, J.S. Miles', M.
Adesnik4 & C.R. Wolf'
'ICRF Lab. Mol. Pharmacol., Department of Biochemistry,
Edinburgh; 2MRC Clinical and Population Cytogenetics
Unit, Edinburgh; 3Dept. Mol. Biol., University of Edinburgh,
UK; and 4Dept. Cell Biol. NYU, New York, USA.
The enzymes encoded by the cytochrome P-450 multi-gene
family play a central role in chemical carcinogenesis. How-
ever, due to the multiplicity of this enzyme system in any
given tissue it is difficult to establish the role of a particular
cytochrome P-450 protein in these reactions. The capacity of
each individual P-450 form in the metabolism of chemical
carcinogens needs to be evaluated.
A potentially powerful approach in such studies is the
expression of cytochrome P-450 cDNAs in yeast, an orga-
nism which can be used directly for mutation studies. To this
end we have isolated a full length cDNA clone for the rat
PB3a gene (P450-IIB gene family). In order to express this
cDNA in yeast the clone sequence under the control of the
Saccharomyces cerevisiae (brewers yeast) alcohol dehydroge-
nase promoter (ADH 1), was incorporated into the 2 micron-
type multi-copy yeast shuttle vector pMA56.
The resultant construct has been shown via Western blot
analysis to produce PB3a protein at a level of between 0.1%-
1% of total yeast cellular protein. The ability of the yeast
expressing this P-450 form to metabolize anticancer drugs
and various procarcinogens to their active mutagenic forms
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Analysis and preclinical pharmacology of the novel
bioreductive alkylating indoloquinone E09
K.L. Kooistra & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB22QH, UK.
E09, 3-hydroxymethyl - 5 - aziridinyl - 1 - methyl - 2 - [1H -
indole - 4, 7 - dione] - prop - P - en - a - ol, is the lead
compound in a series of novel indoloquinone compounds
synthesized as bioreductive alkylating agents (W.N.
Speckamp & E.A. Oostveen, UK and International Patents).
As part of our overall interest in molecules undergoing
bioreductive activation, we have developed an HPLC assay
for E09 and used this to evaluate its preclinical pharmaco-
logy in mice. The drug was administered i.v. at 6mgkg-1.
HPLC analysis was carried out using a Waters Resolve C18
10pm column with a running buffer of 45% methanol in
20mM sodium phosphate buffer, pH 7.4. E09 and internal
standard, E012, were detected by absorption at 280nm.
The projected peak plasma levels were 422ngml-P and
the drug was rapidly eliminated with a half-life of 4.2min.
The volume of distribution was large at 355ml and the
clearance 59mlmin-1. Urine from animals receiving E09
had a bright red appearance, though no parent drug was
detected in urine. This pharmacokinetic profile differs greatly
from the indoloquinone prototype, mitomycin C. When
administered at the same dose, mitomycin C was eliminated
with a half-life of 12min, and exhibited a volume of
distribution of 35ml, clearance of 2mlmin-1 and peak
plasma levels projected at 4.3ygml-1. These results show
that active concentrations of E09 can be achieved in vivo,
though it may be appropriate to modulate pharmacological
behaviour by using alternative delivery methods or modified
analogues.
Gene amplification as a mechanism of resistance to a novel
folate-based thymidylate synthase inhibitor in human W1-L2
cells
B.M. O'Connor, A.L. Jackman, P.H. Crossley & A.H.
Calvert
Inst. Cancer Res., Sutton, Surrey, UK.
We reported previously a mutant L1210 cell line with
acquired resistance (>200 fold) to the TS inhibitor N10-
propargyl-5,8-dideazafolic acid (CB3717). TS was overpro-
duced 45-fold and this was shown to be due to amplification
of the TS gene. A small (2,5-fold) increase in dihydrofolate
reductase (DHFR) was also observed (Jackman et al.,
Cancer Res., 46, 2810, 1986). This resistant cell line has
therefore provided a useful source of murine TS. We report
here six human lymphoblastoid cell lines (WI-L2: Cl-C6)
with acquired resistance (>10,000 fold) to the 2-CH3 ana-
logue of CB3717. This analogue is a 2-fold poorer TS
inhibitor than CB3717, but is 40-fold more cytotoxic. It was
hoped that these WI-L2 cells would overproduce TS in a
manner similar to L1210 and thus be a source of human
enzyme. Resistance was raised by subjecting the cells to
incremental concentrations of the 2-CH3 analogue of
CB3717 and then cloning them in microtitre plates. The
resultant cloned cell lines (WI-L2: C1-C6) were found to
have increased TS activity (200-fold) compared with the
parent line. TS gene amplification was also demonstrated by
the use of a TS cDNA probe. DHFR activity in the cloned
cell lines was not elevated compared with the parent line,
and the DHFR gene was not amplified. Only a 40%
decrease in TS activity was found when the resistant cells
were grown in the absence of the 2-CH3 analogue of CB3717
for >390 generations. The resistant line WI-L2:Cl was
investigated further. This line showed cross-resistance to
other folate-based TS inhibitors e.g., CB3717 and 2-
desamino-CB3717 but was collaterally sensitive to the
DHFR inhibitor methotrexate (MTX). The TS enzyme was
partially purified from both the resistant and sensitive Wl-
L2 cell lines and Kiapps for the 2-CH3 analogue of CB3717
were estimated to be 21.94+0.64 nM (Wl-L2:Cl) and
22.3+0.516nM (WI-L2). It therefore seems unlikely that
resistance is due to the TS enzyme having a decreased
affinity for the 2-CH3 analogue of CB3717. Moreover the
Kiapps of a wide variety of folate-based TS inhibitors using
TS from these resistant cells were similar to those obtained
using TS from the mutant L1210 cells.
The effects of the platinum anti-tumour agents on the renal
response to secondary cytotoxic insult
C. Ewen & J.H. Hendry
Paterson Institutefor Cancer Research, Wilmslow Road,
Manchester M209BX, UK.
Paterson BDF mice were treated with LD50 doses of cis-
platin (15mgkg-1), iproplatin (45mgkg-1) and paraplatin
(150mgkg-1). Animals surviving the period of acute toxicity
were treated at day 14 with the acute nephrotoxin uranyl
nitrate (16mgkg-1) which induces tubule necrosis. The
ability of the renal epithelium to recover from this injury
was assessed by sub-capsular tubule count and thymidine
autoradiography. In control animals uranyl nitrate reduced
the sub-capsular tubule count from 508+5 to 229+4 2 days
after treatment. The sub-capsular count returned to control 7
days after treatment. Recovery was marked by an increase in
cortical labelling indices from control levels of 0.21 +0.03%
to 10.6+1.0% by day 3. Treatment 14 days previously with
iproplatin or paraplatin did not influence the renal response
to uranyl nitrate, however, prior treatment with cis-platin
had a potent inhibitory effect. 7 days after treatment with
uranyl nitrate the sub-capsular count was 208+8 compared
to 490+23 in the uranyl nitrate only group and 338+6 in the
cisplatin only group. The peak labelling index was 5.4+0.5%
in the cis-platin and uranyl nitrate group.
Three months after cisplatin, there was still evidence of a
reduced ability to recover from uranyl nitrate induced
damage.
It is concluded that following LD50 doses cisplatin, unlike
iproplatin and paraplatin, has a significant and long-term
effect on the renal response to a secondary cytotoxic insult.
Characterisation and reversal of weight loss induced by
recombinant human tumour necrosis factor (TNF)
S.M. Mahony & M.J. Tisdale
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
When administered as a single i.v. injection human recombi-
nant TNF produced a dose-related weight reduction that was
accompanied by and directly proportional to a decrease in
both food and water intake. When given as two separate
injections over a 24 h period, hypoglycaemia, hyper-
triglyceridaemia and a decreased level of circulatory FFA
were observed 60 to 90 min after the final injection. The
degree of hypoglycaemia is proportional to both the weight
loss and the decrease in food and water intake.
In order to investigate the mechanism of the weight loss
produced by TNF, animals were dosed orally with either
water alone or a concentrated glucose solution. Weight loss
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weight being accompanied by an increase in total body
water. Administration of a concentrated glucose solution had
no greater effect than water alone in reversing the weight
loss, indicating that the observed hypoglycaemia is not
important in this action of TNF. Weight loss produced by
TNF was also reversed by the i.p. administration of indo-
methacin (10mgkg- ) 2h prior to the TNF injection. These
results suggest that weight loss produced by TNF appear to
be the result of prostaglandin production and dehydration.
Circulatory lipolytic factors in cancer cachexia
MAC 15A with a T/C of 175%. However, in mice bearing
systemic MAC 15A the single dose yielded a T/C of 180%,
whilst the split dose produced >50% cures. The growth
inhibition of MAC 13 following single and split dose sche-
dules was 40% and 65% respectively. The single dose
produced a peak plasma drug level of 24.95 igml 1 and an
AUC of 8.61 pgml-1. The corresponding values following
the split dose schedule were 5.95pgml-1 and 14.22 jugml-1
indicating increased exposure and reduced peak plasma
concentration. The in vivo anti-tumour activity of ADR is
enhanced following split scheduling of the total dose but any
toxic effects on the host of this scheduling need to be
determined.
S.A. Beck and M.J. Tisdale
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
We have utilised a transplantable colon adenocarcinoma of
the mouse (MAC16) as a model of human cancer cachexia.
This tumour produces extensive weight loss in the host at
small tumour burdens (-2% of the total body weight) and
without a reduction in either food or water intake. Weight
loss is associated with a decrease in both carcass fat and
muscle mass which is directly proportional to the weight of
the tumour. Weight loss in this murine model has been
correlated with the production by the tumour of both
lipolytic and proteolytic factors, which are present in the
circulation. Both factors respond to normal control and are
inhibited by insulin and 3-hydroxybutyrate. Using DEAE
cellulose chromatography and gel filtration the lipolytic and
proteolytic factors have been shown to be distinct and to be
separable into a number of fractions. Serum from cancer
patients with extensive weight loss shows an elevated lipoly-
tic activity when compared with normal subjects. Fractiona-
tion of serum from cancer patients using ion exchange
chromatography shows evidence of lipolytic activity which
elutes at the same ionic strength as that produced by the
MAC16 tumour, while serum from normal control subjects
contains no peaks of lipolytic activity in the same position.
This raises the possibility that cachexia in both animals and
humans may be due to circulatory lipolytic factors.
Improved experimental anti-tumour activity of adriamycin by
spilt dose scheduling
N.R. Sleigh, P.M. Loadman, M.C. Bibby & J.A. Double
Clinical Oncology Unit, University of Bradford, Bradford,
West Yorkshire BD7JDP, UK.
In vitro studies in this laboratory have shown increased
cytotoxicity in the murine transplantable adenocarcinoma of
the colon system (MAC) following prolonged exposure to
the anthracycline adriamycin (ADR). This study investigates
the anti-tumour activity and the pharmacokinetics of ADR
following single and split dose scheduling in vivo. NMRI
mice bearing ascitic or systemic MAC 15A or s.c. MAC 13
tumours were treated i.v. in groups of 10 with either one
I0mgkg 1 dose of ADR or four doses of 2.5 mgkg- I at 2 h
intervals. Median survival time (MST) or mean tumour
weights were recorded as appropriate. MST was expressed as
a per cent ratio of experimental over control time, and
tumour weight as per cent inhibition of growth compared to
the control group. Plasma was taken from non-tumour
bearing mice at time intervals up to 24h from commence-
ment of each dose schedule and ADR was extracted by solid
phase chromatography and analysed by HPLC. Drug con-
centration time curves were constructed and AUCs obtained
as an indication of drug exposure. Treatment by both
schedules produced the same effect in mice bearing ascitic
In vitro binding of nitrogen mustard to polyamino acids
A.M. Tacchi-Bedford & C.C. Boyle
DHSS Department of Toxicology, St Bartholomew's
Hospital Medical College, Dominion House, London
EC] 7ED, UK.
Various methods are currently being used for monitoring
human exposure to alkylating agents. We are in the process
of developing an analytical technique for quantitating the
extent of exposure to such compounds as nitrogen and
sulphur mustard by determining the formation of amino acid
adducts in skin and hair samples. In order to identify the
specific sites of reaction of these compounds with proteins,
preliminary in vitro studies were carried out using polyamino
acids as substrates. Nitrogen mustard (HN2) was incubated
with poly-L-histidine, poly-L-valine, poly-L-serine, poly-L-
tyrosine, or poly-L-lysine in 0.1 M sodium phosphate buffer
pH 7.4 at 37°C. The reactions were initiated by addition of
14C-labelled HN2 (106 dpm, sp.a. 22mCimmol-1) to the
incubation mixtures and stopped with ice-cold ethanol. The
polyamino acids were precipitated on glass fibre filters and
the bound radioactivity was counted. The rates of reaction
were similar for all polyamino acids: the maximum degree of
binding was reached between 3 and 4h from the beginning
of the experiment and remained constant up to 6 h. The
most reactive substrate was shown to be poly-L-valine with
3% of the initial radioactivity bound after 1 h, followed by
poly-L-serine and poly-L-histidine (2 and 1.8%, respectively).
Although these data do not necessarily reflect an in vivo
situation, they may provide some information on potential
target amino acids for NH2 and the relevant adducts for
future analytical work.
Computer-aided design of N-(hydroxymethyl) anti-cancer
drugs
W. Mallawaarachchi1, D.E. Parry1, R.J. Simmonds1 &
G.M. Wright2
'Edward Davies Chemical Laboratories, U.C.W.,
Aberystwyth SY23 JNE; and 2Chemical Design Ltd., Unit
12, 7 West Way, Botley, Oxford OX42UA, UK.
Molecular orbital calculations for N-(hydroxymethyl)amides,
including the anti-tumour N-(hydroxymethyl)formamide,
have established that the half-lifes (t,1/2) of these hydroxy-
methylamides at pH 7.4 and 37°C may be reliably estimated
from the N-CH20H bond length, calculated using the
MNDO method. Longer bonds are indicative of more
reactive compounds and, as shown in the table below, this
relationship is approximately maintained when extended to
N-(hydroxymethyl)pentamethylmelamine (the active metabo-
lite from hexamethylmelamine), trimelamol and 1-aryl-3-
(hydroxymethyl)-3-methyltriazenes (e.g. the N-hydroxy-
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these compounds is related to their half-lifes it should now
be possible to assess the anti-tumour activity of analogues by
molecular orbital calculations prior to synthesis.
N-CH20H
Compound bond length/A tl/2min-
N-hydroxymethyl)phthalimide 1.483 0.5
N4hydroxymethyl)dichloroacetamide 1.477 77
N-(hydroxymethyl)chloroacetamide 1.475 1700
N4hydroxymethyl)formamide 1.470 3000
N-(hydroxymethyl)pentamethyl-
melamine 1.487 60
2,4,6-tris[N-hydroxymethyl)methyl-
amino]-1,3,5-triazine 1.488 10
1-(4-carbethoxyphenyl)-3-hydroxy-
methyl-3-methyltriazene 1.495 >> 12
Antibody-mediated radiosensitizer targetting of tumour cells-
conjugate preparation
J. Muir, H.M. Warenius & D.M. Tidd
University of Liverpool, Department of Radiation Oncology,
Clatterbridge Hospital, Bebington, Wirral, Merseyside
L634JY, UK.
The halogenated pyrimidine analogue 5-bromodeoxyuridine
(BrdU) has proved to be an effective radiosensitizing agent
in rapidly dividing cells. The magnitude of radiosensitization
is proportional to the extent of BrdU incorporation into
DNA, thus successful therapy would require high concen-
trations of BrdU to reach the malignant cells but not normal
tissues. More specific cell targetting might be achieved by use
of a BrdU-antibody conjugate, however, direct conjugation
of drug to antibody has limited potential since only a small
number of suitable functional groups are available for
substitution if antibody-binding activity is to be retained. To
increase the molar substitution of BrdU to antibody and
thus the efficacy of the conjugate we have employed poly-L-
lysine as a carrier molecule. BrdU is attached to the free
-NH2 groups of the polymer which is in turn linked to the
antibody using the heterobifunctional cross-linking agent
succinimidyl 4-(p-maleimidophenyl)butyrate in a molar ratio
of antibody to SMPB of 1:5.
Spectrophotometric analysis of BrdU incorporation and
measurement of the number of free -NH2 groups in the
substituted polymer show that -40% of the -NH2 groups
are covalently coupled to BrdU. This results in a water
soluble BrdU-carrier-antibody conjugate. Flow cytometric
analysis has shown that the conjugate is incorporated into
the human colonic adenocarcinoma cell line HT29/5. Further
work is now being carried out to measure the degree of
radiosensitization produced by the conjugate.
Determination of rates of specific adsorptive endocytosis and
non-specific endocytosis of drug antibody conjugates and
their components
M.C. Garnett, C.R.L. Graves & S.L. Smith
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG72RD, UK.
For the development of targetted drug conjugates, it would
be useful to account for the specific cytotoxicity of these
compounds by the quantitation of their intracellular delivery.
Assuming from the kinetics of uptake of antibody (see
accompanying paper) and fluorescent conjugates that this is
by pinocytosis, several possibilities for endocytosis exist.
Either specific or non-specific adsorptive (predominant at
low conjugate concentrations), and non-specific fluid phase
(predominant at high conjugate concentrations).
The non-specific component has been measured by uptake
of radiolabelled components into cells and expressed as an
endocytic index (Ml uptake of medium 10-6 cells h-1), and
the specific uptake of 1251-791T/36 antibody and 1251-791T/
36-HSA-MTX conjugates have been determined using the
quantitative radiolabelling method described in the accompa-
nying paper. These results showed that uptake of HSA (used
as a fluid phase marker) was at an average of 1.9 jul
medium 10-6 cellsh-1, but that HSA-MTX was apparently
taken up at 5.7pl medium 106 cells h-1. The use of varying
quantities of labelled material diluted with varying amounts
of unlabelled material demonstrated a small but significant
amount of membrane bound HSA-MTX. These data
together with rates of antibody and conjugate endocytosis
can be used to assess relative specific and non-specific
endocytic uptake of drug-antibody conjugates.
Flow cytometric estimation of relative bromodeoxyuridine
incorporation as a means of detecting targetted
bromodeoxyuridine in human and hamster cell lines
D. Spiller, J.A. Tidd & H.M. Warenius
University of Liverpool Department of Radiation Oncology,
Clatterbridge Hospital, Wirral, Merseyside L634JY, UK.
As part of a study to investigate the possibility of using
antibodies to target BrdU for radiosensitisation, the colonic
adenocarcinoma cell line (HT29/5) and a chinese hamster
lung line (V79a) were exposed to 0, 3, 30 and 300 imol
BrdU for periods of time ranging from 30min to 7 days.
Relative BrdU incorporation was measured by a two stage
fluorescence technique using a BrdU specific monoclonal
antibody and flow cytometry. The biological effect of BrdU
was measured using clonogenic and 3(4,5-dimethylthiazol-2-
yl)-5-diphenyl tetrazolium bromide (MTT) assays. Following
optimisation for each cell line of MTT test conditions, there
was good correlation with the clonogenic assay in cell
survival curves. There was also a correlation between cell
survival and amount of BrdU incorporated. BrdU incorpora-
tion was shown in cells incubated with BrdU-polylysine
conjugates thus allowing the potential feasibility of BrdU-
polylysine-monoclonal antibody conjugates as vehicles for
selective localisation of BrdU. The use of this technique is
now being extended to confirm uptake of non-ionic oligo-
nucleotide probes into whole cells by the use of BrdU within
the nucleotide sequences.
Biodistribution and tumour localisation of methotrexate and
daunomycin monoclonal antibody conjugates in nude mice
with human tumour xenografts
M.V. Pimm, J.A. Clegg, M.C. Garnett, Y. Ogunmuyiwa,
M.A. Paul & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, NG72RD, UK.
The blood kinetics and tumour localisation of conjugates of
methotrexate (MTX) and daunomycin (DAU) and the
monoclonal antibody 791T/36 have been examined in nude
mice with human tumour xenografts. The antibody moiety of
the conjugates were followed by labelling with 125-I and the
drug moieties using radioimmunoassays.
After radioiodination, the drug moieties were co-
precipitable with the radiolabel using TCA or rabbit anti-
mouse IgG antiserum. Following i.v. injection, serum kine-
tics of both the antibody and drug moieties of both of the
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serum-borne conjugate was confirmed by the co-precipitation
of radiolabel and drug. The radiolabelled antibody moiety of
the conjugate localised in tumour xenografts and the levels
were maintained for up to 4 days. The declining serum levels
and relatively constant tumour levels of radiolabel resulted
in a progressive increase in tumour to serum ratios. Analysis
of tumour levels of the drug moiety showed a similar
pattern, with up to 4% of the injected dose being present per
gram of tumour over the 4 day observation period with
progressively increasing tumour to serum ratios of the drug,
the ratios being virtually identical to those with antibody.
Parallel studies with free drugs showed rapid clearance from
the blood and a maximum of 0.35% of the dose/g of tumour
30min after injection. Control immunoglobulin conjugated
to MTX did not show tumour localisation of either the
antibody or drug moieties.
These studies confirm the in vivo stability of these types of
drug antibody conjugates and demonstrate site-specific tar-
getting of therapeutic agents.
Biodistribution of rcin toxin A chain-monoclonal antibody
791T/36 immunotoxin and influence of hepatic blocking
agents
Using 2 rosette-forming Hodgkin's disease derived cell lines
(L428 and L591) we have studied the physico-chemical
properties of rosettes formed in vitro and made some prelimi-
nary attempt to identify any putative receptor mediating
adherence. Rosettes formed between the Hodgkin's disease
cell lines and allogeneic peripheral blood lymphocytes were
shown to be temperature independent, occurring optimally
between pH5 to 8 and independent of active metabolic
processes. The majority of the rosetting populations were T-
cells (CD3+), comprised ofequal numbers ofTh and T. cells.
B-cells were poor at forming rosettes and monocytes at least
equally as good as T-cells. Removal of sialic acid from the
Hodgkin's cell surface significantly reduced rosetting, but it
was not possible to inhibit rosetting with N-acetyl neuram-
inic acid. Pre-incubation of L428 cells with peripheral blood
membrane fragments significantly inhibited their rosette
forming ability with allogeneic lymphocytes. In a preliminary
attempt to identify any molecular structure(s) at the L428
cell surface, responsible for mediating adherence, we have
demonstrated in binding assays the molecular weights of a
number of 1125 labelled L428 surface components binding to
peripheral blood membrane fragments.
Izabella Z.A. Pawluczykl, Vera S. Byers1' 3, R.W.
Baldwin', M.V. Pimm' & A. Perkins2
1Cancer Research Campaign Laboratories and 2Department
of Medical Physics, University of Nottingham, UK; and
3Xoma Corporation, Berkeley, California, USA.
An immunotoxin constructed by conjugating ricin A chain
to monoclonal antibody 791T/36 specifically suppresses
growth of human tumour xenografts and is in clinical trial
for the treatment of colorectal cancer. The objective of
immunotoxin therapy is to target the cytotoxic moiety
(ricinA chain) to tumour cells and this requires that the
product localizes efficiently in tumours. In this respect
ricin A chain - 791T/36 antibody conjugates (RTA-791T/36)
have a markedly altered biodistribution when compared to
unconjugated antibody. This is principally manifest as
hepatic uptake of immunotoxin which appears to be
controlled by the ricinA chain (RTA) moiety. This was
established by comparing the blood survival and organ
distribution of immunotoxin with that of ricinA chain and
free antibody using preparations in which either the RTA or
antibody alone or as components of the immunotoxin were
radiolabelled. Hepatic uptake is dependent upon Kupffer cell
recognition of mannose-containing oligosaccharide structures
on the RTA moiety of immunotoxin. Mannose-containing
blocking agents given with immunotoxin were shown to
prolong circulation time of the immunotoxin in blood and
reduce liver uptake. Effective blocking agents include glyco-
proteins such as ovalbumin, ovomucoid and mannose-
containing compounds including mannosyl-lysine. These
agents specifically inhibit hepatic uptake of immunotoxin so
altering biodistribution. Immunotoxin administered together
with blocking agents preferentially localises in human
tumour xenografts compared with immunotoxins alone and
this should improve therapeutic efficacy.
Investigation of the Reed-Sternberg/lymphocyte rosetting
reaction
D.J. Flavell & D.H. Wright
Department of Pathology, Southampton General Hospital,
Southampton S094XY, UK.
The association between Hodgkin tumour cells and T-
lymphocytes to form rosettes is of unknown significance.
Peripheral blood mononuclear cells (PBM) from relatives of
women with familial breast cancer form multinucleate giant
cells (MGC) in vitro
A.R. Morton1' 2, N.G. Testa3, S.A. Wallace4, P. Burns4, J.
Birch4 & A. Howell2
1University Department of Medicine, 2CRC Departments of
Medical Oncology, 3Experimental Haematology, and
4Department of Epidemiology, Christie Hospital and
Paterson Institute, Manchester, UK.
When cultured in vitro human PBM fuse to form MGC
which resemble foreign body giant cells and osteoclasts. This
phenomenon has been shown to occur commonly in women
with breast cancer (BC) but infrequently in unaffected
controls (Al Sumidiae et al., Br. J. Surg., 73, 839, 1986). The
aim of this study was to determine whether MGC formation
antedated the development of BC by culturing PBM from
women at 50% lifetime risk by virtue of a strong family
history (FH at least 2 affected first degree relatives). Ten ml
peripheral venous blood was collected aseptically from 40
women with BC, 40 healthy control women with no FH of
BC, and 20 first degree relatives of women with a strong FH
of BC. PBM were separated over a Ficoll-Hypaque gradient.
Without further purification 2 x 106 cellsml-1 were incu-
bated in Iscove's modified Dulbecco's medium plus 15%
foetal calf serum at 37°C in an atmosphere of 5% CO2/95%
air. Medium was changed weekly. MGC (>3nuclei/cell)
began to appear after 7-10 days and cultures with >2MGC/
590 1i2 were counted as positive. At 17 days the mean
number of MGC in positive cultures was 24.2+5.0 (s.d.
n=15) and was 43.1+7.3 at 24 days. MGC synthesised an
osteoclast marker and tartrate resistant acid phosphatase.
MGC formed in 30 of 40 (75%) cultures from women with
BC, but only in 7 of 40 (17.5%, 0.001 <P<0.01) healthy
age-matched controls with no FH of BC. MGC were seen in
14 of 20 (70%) of cultures from sisters (2 of 5) and
daughters (12 of 15) of women with BC and a FH
(0.001 <P.0.01 compared with controls). These data sug-
gest that the propensity to form MGC under these culture
conditions may antedate the development of BC. Further
investigation of this phenomenon as a possible marker of
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In vitro stimulation of B lymphocytes from peripheral blood
in the production of human-human hybridomas
H.Y. Youd, D. Spiller & H.M. Warenius
University of Liverpool Department of Radiation Oncology,
Clatterbridge Hospital, Bebington, Wirral, Merseyside
L63 4JY, UK.
An important part of the successful production of mouse-
mouse hybridomas, has been the ready supply of stimulated
B lymphocytes. In the human system it is necessary to
stimulate B lymphocytes in vitro prior to fusion. This has
been attempted using the mitogens phytohemagglutinin
(PHA), as T cell mitogen, pokeweek mitogen (PWM), a T/B
cell mitogen, and tetanus toxoid, as a means of B cell
activation. Human peripheral lymphocytes were isolated
from healthy volunteers. The total number of immuno-
globulin (Ig) secreting cells and those specific for tetanus
toxoid was assessed by the use of a filter plaque assay. In
order to detect activated B cells within the mixed lymphocyte
population, a flow cytometric technique simultaneously
measuring DNA content and cell surface markers was
adopted. Following mitogen stimulation the DNA profiles
showed an increased number of cells in S G2 M phase
evident in both B and non-B cell populations. This was
optimal after 72h incubation with 1 pigml - PHA in 5%
human AB serum at 1 x 106 cellsml-1. Stimulation was
found to be preferable in terms of fusion frequency and
hybridoma production with PHA. The effect of B cell
activation on specific Ig production is under continued
examination before and after fusion.
Posters
Analytical and formulation studies on 1,4-bis(2'-chloroethyl)-
1,4-diazabicyclol2.2.11-heptane dihydrogen dimaleate
(NSC262666)
M.J. Griffin, J.A. Slack & P. Kestell
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, University of Aston, Birmingham B4 7ET,
UK.
The synthesis and antineoplastic activity of a series of 1,4-
bis(2' - haloethyl) - 1, 4, diazabicyclo - [2.2.1] - heptane
dications has been previously reported by Pettit et al. (J.
Pharm. Sci., 68, 1539, 1979). The optimized HPLC con-
ditions consisted of a phenyl column (100mm x 8 mm) with
a mobile phase of 0.3 mm sodium naphthalene sulphonate in
water, adjusted to pH 1.9 with phosphoric acid. Detection
was at 260 nm with the 1,4-bis(2'-chloroethyl)-1, 4,
diazabicyclo-[2.2.l]-heptane ion eluting as a negative peak
with a capacity factor (K') of 0.33. The injection volume of
0.025 ml gave a lower limit of detection of 0.8 mgml-1 and
calibration curves were linear over the concentration range
4.0 to 20.0mgml-1. The coefficient of variation for replicate
injections (n =6) was 5.1% at 2mgml -1 and 4.0% at
10mgml-'. The HPLC method was stability-indicating for
NSC262666 with the reported degradation product, N,N'-
bis(2'-chloroethyl) - piperazine, having a K' of 0.72. Lyophi-
lized preparations of NSC262666 proved to be both chemi-
cally and physically unstable at 50°C and room temperature.
Aqueous solutions of NSC262666, sterilized by terminal
filtration, were found to be stable at 4°C for greater than 12
months. An 8mgml-P solution of NSC262666 in 5% dex-
trose exhibited no degradation, at room temperature, over a
period of 48 h. NSC262666 was formulated for phase I
clinical trial as a 50mgml-1 aqueous solution.
sised in the hope that the reduced potential for H-bonding
would result in a more soluble compound. This was indeed
found to be the case and the compound was not acutely
toxic to the liver and kidneys of mice. This fact, together
with the good in vitro activity of this analogue, led us to
make other modifications at the 2-position. A number of
secondary and tertiary amines were synthesised, of which 2-
NHCH3 (15 =0.18 uM) and 2-NH(CH2)OH (I15 =0.19 LM)
were the most potent TS inhibitors. All were poor inhibitors
of cell growth. A wide range of other 2-substitutions were
made and we concluded that TS can tolerate quite large
substituents at the 2-position although electron withdrawing
or bulky groups confer poor cytotoxicity. The most potent
TS inhibitors are shown below.
2-Substitution TS Iso(MiM) L1210IC50 (PM)
-NH2 (CB3717) 0.02 3.4
-OLCH3 0.028 1.9
-CH3 0.04 0.085
-CH2F 0.096 0.37
-CH20H 0.098 5.0
-SCH3 0.116 13
-CH2CH3 0.136 2.5
-OCH2CH3 0.146 > 100
-H (desamino-CB3717) 0.166 0.4
-CL 0.2 67
-Phenyl 0.22 > 100
The 2-CH3 compound is a potent TS inhibitor as well as
very cytotoxic and water soluble, properties that make this a
very interesting compound for further study.
Antibody inhibition of cholesterol 7a hydroxylase
2-desamino-2-substituted analogues of 10-propargyl-5,8-
deazafolate (CB3717) as inhibitors of thymidylate synthase
(TS)
J.A.M. Bishop', A.L. Jackman', L. Hughes2,
P. Marsham2, T.R. Jones1 & A.H. Calvert'
1Institute Cancer Research, Sutton, Surrey; and 2L.C.L,
Macclesfield, UK.
The TS inhibitor, CB3717, was withdrawn from clinical
study because of unpredictable liver and kidney toxicities. As
the kidney toxicity, at least, was attributable to the poor
water solubility of CB3717, 2-desamino CB3717 was synthe-
E.R. EldredgeI2, B. Jackson1, K.E. Suckling'
& C.R. Wolf2
1Department of Cellular Pharmacology, Smith Kline &
French Research Ltd, The Frythe, Welwyn, Herts AL69AR;
and 2ICRF Lab. Mol. Pharmacol. Department of
Biochemistry, University of Edinburgh, Edinburgh EH8 9XD,
UK.
High levels of bile acid secretion have been associated with
individual susceptibility to colon cancer. The rate limiting
step for bile acid synthesis has long been accepted to be that
catalyzed by cholesterol 7a hydroxylase. This minor species
of cytochrome P-450 has been shown to be unique through
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substrate specificity studies and is not readily inducible by
phenobarbital or 3-methylcholanthrene. We screened nine
antibodies as inhibitors of cholesterol 7a hydroxylase, includ-
ing those raised against cytochromes P-450 from the gene
families I, IIA, IIC and III. Of three antibodies to proteins
within family IIC (PBla, PBlb and PB2a), an antibody raised
against PB2a, a male specific cytochrome P-450 expressed at
adolescence, readily phosphorylated, and also not inducible
by phenobarbital, could completely inhibit the microsomal
7a hydroxylation reaction. This finding, together with the
fact that cytochromes P-450 are a large mutigene family,
suggests that cholesterol 7a hydroxylase, being a unique P-
450, may share some structural homology with other P-450's
in the P450-IIC gene family.
Some biological properties of 2-desamino-2-substituted-5,8-
deazafolates that inhibit thymidylate synthase (TS)
A.L. Jackman', G.A. Taylor1, R. Moran2,
J.A.M. Bishop', K. Pawelczakl, K. Balmanno1 & A.H.
Calvert'
'Institute Cancer Research, Sutton, Surrey, UK; and
2Children's Hospital of Los Angeles, CA, USA.
In the search for more potent and more water soluble
analogues of CB3717 we have synthesised and tested a
number of compounds possessing alternative substituents to
the 2-amino function (Bishop et al. & Newell et al., accom-
panying abstracts). The two best TS inhibitors made were
the 2-OCH3 and 2-CH3-substituted compounds which were
only 1.4 and 2-fold less active than CB3717 (Ki=4 nM). The
2-CH3 analogue was notably the most cytotoxic compound
(IC0 =0.085 uM; 2-OCH3IC,=1.9 1iM) although the activity
of both could be prevented by co-incubation with thymidine
suggesting that TS is their sole locus of action. Using a
whole cell TS assay we demonstrated that the 2-CH3 ana-
logue (_0.5 1iM for 4h) caused prolonged inhibition of TS
after resuspension of cells in drug-free medium. This is
assumed to be due to the formation of polyglutamate
metabolites that cannot be effluxed from the cell. Indeed the
2-CH3 analogue has substrate activity for folylpoylglutamate
synthetase (FPGS) (Km=60,uM) similar to that of CB3717
(Km=40yM) where polyglutamation in L1210 cells has
been conclusively demonstrated. In contrast the 2-OCH3
analogue could not continue to inhibit TS after the removal
of extracellular drug (100,uM for 4h) and this correlates
with poorer FPGS substrate activity (Km= 193 ,M)
although slower transport into the cell may be an additional
factor. Synthesis of synthetic polyglutamates of the 2-CH3
compound has shown that they are substantially better
inhibitors of TS (- 100-fold) than the monoglutamate form
(similar to that found with CB3717 polyglutamates). Intra-
cellular metabolism to polyglutamates is an important deter-
minant of cytotoxicity and all 2-desamino-2-substituted
CB3717 analogues so far tested for FPGS substrate activity
show activity that correlates well with cytotoxicity. Indeed
polyglutamation seems to represent an essential activation
step for many of the weaker TS inhibitors. For example 2-
CHR3-5,8-dideazafolate is 112-fold less active than the propar-
gylated compound described above but equally cytotoxic and
this may be accounted for by its very good FPGS substrate
activity (Km=10M).
Pharmacokinetic and toxicity studies with C2-desamino
C2-substituted analogues of the antifolate
N10-propargyl-5,8-dideazafolic acid (CB3717)
D.R. Newell1, R.J. Maxwell2, J.R. Griffiths2, G. Bisset',
L. Hughes3 & A.H. Calvert'
'Institute of Cancer Research, Sutton, Surrey; 2St Georges
Medical School, Tooting, London; and 3ICI Plc,
Macclesfield, UK.
In the search for a non-nephrotoxic and non-hepatotoxic
antifolate thymidylate synthase (TS) inhibitor a series of C2-
desamino-C2 one carbon substituted CB3717 analogues have
been synthesised. Of these, the C2-CH3 analogue is only 2
fold less potent than CB3717 as a TS inhibitor yet 40 fold
more toxic to tumour cells grown in vitro. Ther toxicities of
CB3717 and analogues substituted at the C2 position with
-H, -CH3, -CH2F and -CH2OH have been compared in
mice. CB3717 (100 mgkg-1 i.v.) caused both liver (raised
alanine transaminase) and kidney (raised urea and creati-
nine) damage whilst the analogues induced no toxicity. This
may be due to their greatly enhanced (>100 x ) solubility at
physiological pH. The pharmacokinetics of CB3717
(100mgkg-1 i.v.) and the C2-H and C2-CH3 analogues
(500mgkg-1) were compared in mice with sample analysis
by HPLC. CB3717 was cleared slowly from the plasma
(0.31 h-1 kg-1t1/2 90 min) whilst the analogues were cleared
rapidly (C2-H 4.81 -1hkg-1 t1/2 21 min, C2-CH3
2.51 h-1 kg- t'12 16min). For all three compounds 0-24h
urinary excretion accounted for 20-30% of the dose, how-
ever, faecal elimination of the two analogues was more
extensive (50% dose 0-24h) than with CB3717 itself (20%
dose 0-24 h). The enhanced plasma clearance and faecal
excretion of the analogues was probably a result of their lack
of hepatotoxicity. Pharmacokinetics have also been studied
non-invasively in mice (500 mgkg-1 i.v.) and rats
(100mgkg-1 i.v.) by in vivo 19F-NMR spectroscopy using
the 2-CH3-6'-CH3 CB3717 analogue. In both species com-
pound could be detected in the upper abdomen shortly after
injection (rats <2min). As 70-80% of the dose was excreted
in the bile within 1 h the signal was presumably due to
compound undergoing biliary elimination. These studies have
identified C2-desamino-C2 substituted analogues of CB3717
as non-hepatotoxic and non-nephrotoxic antifolates and
have established further the viability of 19F-NMR in phar-
macokinetic monitoring.
In vivo inhibition of thymidylate synthase by
C2-desamino-C2-substituted analogues of N'0-propargyl-5.8
deazafolic acid (CB3717)
G.A. Taylor, A.L. Jackman, K. Balmanno & A.H. Calvert
Institute Cancer Research, Sutton, Surrey, UK.
The evaluation of the efficacy of TS inhibitors in murine
tumour systems is complicated by the high levels of circulat-
ing thymidine in the host mice. The amount of thymidine in
mouse plasma is sufficient to circumvent the activity of TS
inhibitors such that although TS may be effectively inhibited
tumour cells may still, for a limited period, be able to
replicate and synthesise new enzyme. Prolonged exposure is
therefore essential to induce measurable antitumour res-
ponse. The properties of C2-desamino-C2-substituted ana-
logues of CB3717 vary with respect to TS inhibition,
pharmacokinetics, and polyglutamation (Bishop et al.,
Newell et al. & Jackman et al., accompanying abstracts).
The inhibition of TS activity within intact cells from mice
following in vivo treatment with such analogues has been
investigated with respect to dose and time. This has demon-
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(assumed to be polyglutamated) forms of the analogues in
determining the inhibitory activity seen in vivo. An i.v. dose
of 240mgkg-1 of CB3717 was needed in order to achieve
50% inhibition of TS activity at 2h in ascitic L1210 cells.
The C2-desamino (A) and C2-CH3 (B) analogues were more
effectively retained in cells than CB3717 despite their rapid
clearance. A similar degree of inhibition was achieved with
only 27 and 2mgkg-1 of A and B respectively. In order to
obtain >80% inhibition of TS (at 2 h) 430, 96 and
40mgkg-1 was required for CB3717 and the two analogues
A and B. The extension of this degree of inhibition of TS
over a 12 h period required a dose > 1,000 mgkg-1 of A but
we found that <100 mgkg - of B was sufficient. It is
apparent that the multiple daily dosing of mice will not
afford inhibition ofTS throughout the treatment period. From
these studies it is hoped that equipotent (with respect to TS
inhibition) protocols may be defined which will permit the
rational comparison of antitumour efficacy and toxicity of
the analogues.
A potential new in vivo metabolite of VP16 (etoposide)
H.P. Henneberry & G.W. Aherne
Department of Biochemistry, University of Surrey, Guildford,
Surrey GU25XH, UK.
Methanol extracts of plasma from patients treated with
VP16, per os or i.v., were injected onto a 250 x 4.5mm
HPLC column packed with C18, 5i u diameter, silica gel and
connected to a UV detector. Samples were eluted in
methanol-water-glacial acetic acid (50:48:2) at a flow rate
of 1 mlmin- I and peaks were detected at 254 nm. Retention
times (RT) for cis-hydroxy acid VP16, VP16, VP16 aglycone
and VM26 (Internal Standard) were 6.8, 9.2, 20.2, 22.7 min
respectively. All patients' plasma extracts tested were found
to have a peak corresponding to hydroxy acid VPl6. Also, an
unexpected late running peak of RT 31.6min, not corres-
ponding to any of the standards or analogues tested, and not
present in drug-free plasma extracts, was seen in those
plasmas.
Approximately 1 mg of this plasma component was
collected and the results of preliminary analyses (organic
spot tests, ELISA, IR, MS) revealed the component to be a
non-immunoreactive aglycone related to the parent drug.
Mass spectrometry indicated that the compound comprised
two main fragment molecules of m/z 311 and 185. The
compound did not contain quinone or semi-quinone groups
but could possibly be a catechol derivative of VP16.
Recent work suggests that, besides its known interactions
with topoisomeraseII, VP16 may have an alternative mode
of action involving conversion of the parent drug to cyto-
toxic intermediates. Several such potential intermediates have
been identified in vitro but not yet in vivo. It remains to be
determined whether our plasma component is an in vitro
breakdown product or whether it is an as yet unidentified in
vivo metabolite and, if so, whether or not it is cytotoxic.
Bioreduction of m-Azidopyrimethamine (MZP) in mouse
tissue homogenate
F.D. Kamali, A. Gescher & J.A. Slack
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
MZP, a potent lipophilic inhibitor of dihydrofolate reduc-
tase, is currently undergoing phase II clinical evaluation. It is
an unusual drug molecule in that it contains an azido
moiety. Azides are prone to chemical reduction, which in the
case of MZP leads to m-aminopyrimethamine (MAP) and is
accompanied by loss of anti-neoplastic activity. Here the
hypothesis has been tested that the liver is the organ in
which MZP is deactivated by enzymatic reduction. MZP
(53,M) was incubated in a final volume of 0.79ml with
hepatic homogenate, 12,000g supernatant, mitochondria or
microsomes (equivalent to 0.1 g liver wet weight) obtained
from male BALB/c mice. MZP and MAP were measured by
HPLC. MZP was rapidly metabolised to MAP in the whole
homogenate and the postmitochondrial fraction, but not in
microsomes or mitochondria. Within 30min 79 +7% (mean
+s.d., n=9) of MZP was reduced by the homogenate.
Homogenates of the following tissues were also able to
reduce MZP, values in brackets are the amount +s.d. (n=3)
of MAP generated within 30min as percentage of the
amount of MAP found in liver homogenate: Kidneys
(31.0+1.2), heart (17.4+3.4), intestine (6.7+3.0), spleen
(4.5+1.0), and lung (3.1 +0.3). Reduction of MZP was also
detected in tissue homogenate after heat-inactivation of
enzymes, but it did not exceed 10% of the values quoted
above. The results suggest that MZP is bioreduced in hepatic
and extrahepatic tissue and that this reduction consists of a
minor chemical and a major enzyme catalysed component.
Assessment of serological assays for use in ovarian cancer
(OCA)
J.E. Roulston1, J. Fisken', A. Bowman2
& R.C.F. Leonard2
tUniversity Department of Clinical Chemistry, Royal
Infirmary, Edinburgh; and 2University Department of
Clinical Oncology, Edinburgh, UK.
PLAP appears to be of little value as a serological marker
used alone to monitor OCA (Fisken et al., Clin. Sci., 73,
(suppl. 17), 9, 1987). However its additive value in combined
assays has been alluded to by other workers. We have
assessed the value of sequential assays for CA125 and PLAP
in the management of clinically advanced OCA. Both CA125
and PLAP activity (PLAP-A) and concentration (PLAP-C)
were measured in 397 samples over time from 87 patients
(FIGO 1-7, 11-5, 111-55, IV-20). Active disease was present at
the time of sampling in 261 instances. CA125 detected 73%
(190/261) of the true positive (TP) samples with only 6 false
positive (FP). When the remaining 71 samples were assayed
by PLAP-A 40 were TP. Of the 31 'double negatives' 13
were TP for PLAP-C. Thus sensitivity apparently increases
from 73% to 93% using all 3 assays. However, analysis of
all 397 samples indicated significant numbers of FP with
PLAP-A and PLAP-C. The predictive power of a positive
result actually falls from 97% with CA125 alone to 76% by
adding in PLAP assays. Similarly the FN rate for PLAP is
high therefore predictive power of a negative result rose only
from 65 to 76%. These data indicate that the PLAP assay is
detrimental to the resolving power of CA125 alone despite
attractive figures for apparent sensitivity.
Urinary pseudouridine (PSU) levels in breast cancer
A. Hardcastle1, W. Aherne1, A.Y. Rostom2 & R. Phipps3
1University of Surrey, Guildford GU25XH; 2St Luke's
Hospital, Guildford GU13NT; and 3Queen Aexandra
Hospital, Portsmouth P06 3LY, UK.
Modified nucleosides such as PSU have been proposed as
markers for several common solid tumours (Speer et al.,
Cancer, 44, 2120, 1979) but its value as a marker in breast
cancer has not been extensively investigated. Urinary PSU244 TWENTY-NINTH ANNUAL MEETING OF THE BRITISH ASSOCIATION FOR CANCER RESEARCH
was measured by HPLC after preliminary isolation on
Affigel columns (Kuo et al., J. Chromatogr., 145, 383, 1978).
We have confirmed that measurement of a random urine
sample is comparable with a 24h urine collection, if the PSU
is expressed in relation to creatinine concentration, i.e. nmol
PSU umol-I Cr. Our laboratory normal range was 12.6-26.4
units. PSU levels do not display any circadian rhythm or
alter through the menstrual cycle. To test the efficiency of
PSU as a preclinical cancer marker, urinary levels were
measured in 24 women who subsequently developed breast
cancer each with 10 matched controls (Bulbrook et al.,
Breast Cancer Res. & Treat., 7 (Suppl.), 5, 1986). The
urinary PSU levels in the 'pre-cancer cases' were not signifi-
cantly different from the controls. We measured urinary
PSU levels in patients before and after primary surgery for
breast cancer and compared them with patients undergoing
other major surgery. PSU levels were frequently not elevated
above normal initially and did not fall after treatment. Also,
PSUs were measured in 30 patients receiving post-operative
radiotherapy for breast cancer; 43% had elevated urinary
PSU (30-71 units). There was a non-significant tendency for
higher levels with increased primary tumour size. PSU levels
did not correlate with disease state as assessed by metastatic
survey:
In other malignancies it has been reported that elevated
excretion of PSU is a negative prognostic factor correlating
with shorter survival time (Rasmuson et al., Bull. Mol. Biol.
Med., 10, 143, 1985). The importance of markedly increased
PSU in individual breast cancer patients can only be deter-
mined by continued 'follow-up' of these subjects.
has a unique and extensive pattern of metabolism involving
glucuronidation. There is little work relating the pharmaco-
kinetics and metabolism of cytotoxic drugs to response or
toxicity for a number of reasons: inconvenience of carrying
out full pharmacokinetic studies; cost; problems with drug
assay; insufficient patient numbers; unresponsive disease/
ineffective drugs. A prospective randomised trial in advanced
breast cancer comparing epirubicin at 2 doses (50 mgm 2
and 100mgm-2) is underway locally. A single plasma
sample was taken in 43 patients 30min following bolus
administration of epirubicin. Using a sensitive and specific
HPLC assay it was possible to detect the parent compound
and 5 metabolites. Nineteen patients are assessable for
response (CR+PR) at 27 weeks following initiation of ther-
apy; high dose, 6/9 response; low dose, 4/10 responses.
Comparing high dose and low dose groups, there was no
significant difference in parent drug concentrations
(82 ngml-1 vs. 67 ngml-1) or in metabolite levels (total
fluorescent compounds 241 ngml-1 vs. 203 ngml-1). There
were no correlations between drug levels and responses
although the single patient with a CR had a high epirubici-
nol level (more than 3 stand deviations from the mean). 9
patients have had multiple samples taken following identical
doses and there was wide intra-individual variation in drug
and metabolite levels from course to course.
Large patient numbers will need to be recruited to reveal
any correlation between plasma drug concentration and
response due to intra and inter individual variation in drug
handling.
Characteristics of a breast cancer antigen isolated from
patients' sera
C. O'Sullivan & M.R. Price
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG72RD, UK.
The anti-breast carcinoma monoclonal antibody, NCRC-11,
defines a family of high molecular weight glycoproteins
(>400kD) associated with malignant cells and specialised
normal secretory epithelia. These components have also been
found to be elevated in the circulation of breast cancer
patients.
Pooled serum from primary breast carcinoma patients was
fractionated by affinity chromatography using Sepharose-
linked NRC-11 antibodies. Non-specifically bound material,
in particular human IgG and IgM, was separated from
NCRC-l1 defined antigen by gel filtration using Sephacryl
S-300 chromatography after reduction of the sample with
dithiothreitol, DTT (antigenic material being unaffected by
DTT). Similar fractionation of a pool of serum from normal
age and sex matched donors failed to produce any detectable
NCRC-11 defined antigen.
The purified NCRC-11 defined antigen from patients'
serum was characterised by SDS PAGE and Western blot-
ting, by epitope mapping studies using a panel of reactive
monoclonal antibodies and by enzyme digestion and lectin
binding tests. The characteristics of this antigen from
patients' serum were comparable to those of antigen pre-
parations from primary tumour tissue.
Plasma epirubicin estimation as a predictor of response in
breast cancer
D.J. Kerr, G.J. Morrison, N. Lawson, J. Cassidy,
E.M. Rankin & S.B. Kaye
Department of Medical Oncology, University of Glasgow,
UK.
Although epirubicin is structurally similar to doxorubicin, it
Changes in proliferative activity in the normal human breast
during the menstrual cycle and with age
G.T. Williams', R.J. Watson1, M. Harris2, C.S. Potten3
& A. Howell4
Departments of 'Surgery, 2Pathology, 3Epithelial Biology
and 4Medical Oncology, Christie Hospital, Wilmslow Road,
Manchester M20 9BX, UK.
Events which occur early in the reproductive life (e.g. early
menarche) of the female are associated with risk of breast
cancer (BC) in later life. Korenman (Cancer., 46, 874, 1980)
proposed that luteal phase progesterone (P) was antiprolifer-
ative and that the early onset of anovular cycles led to the
unapposed stimulation of epithelial cells and thus increased
risk. We have tested the hypothesis that P is antiproliferative
by relating the labelling (LI), mitotic (MI) and apoptotic
(Al) indices of histologically normal breast tissue to the day
of the menstrual cycle, age and serum P values in 122
women undergoing opertions to remove fibroadenomas
(n=116) or reduction mammoplasty (n =6). Thirty-three
were taking the oral contraceptive pill. Thin tissue slices were
incubated with tritiated thymidine (37 kBqnml-1) and pro-
cessed for autoradiography. More than 1,000 cells were
counted to determine the LI, MI and AI for each sample.
The LI ranged from 0-11.5% was cyclic with a maximum on
day 20.8 and declined with age (0.7% per decade). The MI
ranged from 0-0.6% with a maximum on day 21.5 and
declined at a rate of 0.05% per decade. The AI was
unrelated to the menstrual cycle but significantly declined
with age. There was no significant effect of the contraceptive
pill on the proliferative indices. Maximum LI was associated
with high serum P values. These data indicate that the
maximum proliferative rate of mammary epithelium occurs
in the luteal phase of the cycle and suggests that P is not
antiproliferative. They support the studies of Henderson et
al. (Cancer, 56, 1206, 1985) which show that the early onset
of regular (and hence ovular) cycles are related to risk of
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Verapamil resistance in a mouse tumour cell line
P.R. Twentyman, N.E. Fox & K.A. Wright
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge, CB22QH, UK.
The calcium transport blocker, verapamil (VRP) is an effec-
tive modifier of resistance to adriamycin (ADM) and vincris-
tine (VCR) in many multi-drug resistant (MDR) cell lines. In
order to study the mechanism of such modification we have
derived a VRP resistant subline (EMT6/VRP) of the mouse
tumour cell line EMT6. Subline EMT6/VRP is 3.9 fold
resistant to VRP (ID50 =94 igml-1 cf. 24 Mgml-1) but does
not show cross-resistance to ADM or VCR. Similarly an
MDR subline (EMT6/AR1.0) is resistant to ADM and VCR
but not to VRP. Whereas EMT6/ARl.0 hyperexpresses the
mRNA for P-glycoprotein, EMT6/VRP does not. The
accumulation of 3H-VRP by EMT6/VRP is increased com-
pared with the parent line whereas that by EMT6/ARl.0 is
slightly decreased. The accumulation of 3H daunomycin on
the other hand is increased 2 to 3 fold compared with the
parent line in EMT6/VRP but is only 22% of the parent in
EMT6/AR1.0. The sensitivity of all 3 cell lines to ADM is
enhanced by the addition of 6.6 MM VRP (parent=11.0 fold;
EMT6/ARl.0=8.8 fold; EMT6/VRP=6.1 fold).
We are currently studying the cross-resistance of EMT6/
VRP to other resistance modifiers.
It appears that resistance to VRP occurs via a different
mechanism to classical MDR and that VRP-resistance leads
to a partial reduction in the ability of VRP to sensitise cells
to ADM.
Verapamil decreases the sensitivity to adriamycin of an
adherent small cell lung cancer cell line in vitro
R. Milroy', J. Plumb', S.W. Banham2 & S.B. Kaye'
'University Department of Medical Oncology, Glasgow; and
2Department of Respiratory Medicine, Royal Infirmary,
Glasgow, UK.
We have derived an adherent small cell lung cancer (SCLC)
cell line from a skin metastasis of an untreated patient. This
cell line grows in culture as a monolayer in Waymouth's
medium supplemented with 10% FBS. This cell line has been
fully characterised by pathological and immunocytochemical
examinations and is tumorigenic in nude mice showing
classical features of intermediate small cell lung cancer.
We have determined the chemosensitivity of this cell line
to adriamycin by an assay based on the reduction of a
tetrazolium dye, MTT. The ID50 for a 24h exposure to
adriamycin was 3.0 x 10-8M. However, exposure to adria-
mycin for 72h decreased the ID50 by - 50 fold to
6.0 xO10 M.
The calcium antagonist verapamil has been shown to
increase the sensitivity of some cell lines to adriamycin.
However, in this cell line exposure for 72 h to adriamycin in
the presence of verapamil (6.6MM) decreased the sensitivity
by about 3 fold. In contrast, incubation of cells for 24h in
the presence of verapamil (6.6MM) alone prior to a 24h
exposure to adriamycin and verapamil increased the sensitiv-
ity by -3 fold. Clearly this adherent SCLC cell line will be
of value in our studies to elucidate the role of verapamil in
the treatment of SCLC.
Phenotypic stability of a tamoxifen resistant variant of the
ZR-75-1 human breast cancer cell line
H.W. Van den Berg', Maria Lynch1, G.R. Dickson2
& J. Nelson3
Departments of 'Therapeutics and Pharmacology, 2Anatomy,
and 3Biochemistry, The Queen's University of Belfast, UK.
We have maintained the ZR-751 human breast cancer cell
line in the continual presence of tamoxifen (2-4MM), for 2
years. After 6 months oestrogen receptor (ER), expression by
tamoxifen exposed cells (designated ZR-75-9al), had fallen
from 225+19 to 56+12fmolmg-1 protein as determined
using a whole cell binding assay. After a further 18 months
routine culture in the presence of 4MM tamoxifen both ER
and progesterone (PGR), receptors had fallen to undetec-
table levels and this was accompanied by a marked reduction
in sensitivity to antioestrogens.
Under phase contrast microscopy ZR-75-9al cells appear
smaller than the parent line, tending to grow in 'islands'
containing mounds of cells. Transmission electron micro-
scopy revealed a marked reduction in intra-cellular lipid.
Tonofilaments and desmosomes have not been observed. 9al
cells maintained in medium devoid of tamoxifen or oestro-
genic activity (phenol red free medium containing dextran
charcoal stripped serum), remained ER and PGR negative
and tamoxifen resistant for at least 3 months. In contrast,
cells transferred to drug free 'complete' medium became ER
and PGR positive and tamoxifen sensitive within one month.
We conclude that prolonged exposure of ZR-75-1 cells to
tamoxifen does not result in the selective loss of ER positive
cells but to a suppression of ER expression with consequent
loss of tamoxifen sensitivity. Our data further suggest that
recovery of ER and PGR levels only occurs in the presence
of oestrogenic stimuli.
Double-strand break induction and radiosensitivity in human
tumour cell lines
A.M. Cassoni, J. Eady, L.R. Kelland, T.J. McMillan &
J.H. Peacock
Radiotherapy Research Unit, Institute of Cancer Research,
Clifton Avenue, Sutton, Surrey SM25PX, UK.
Current evidence suggests that of the lesions induced in
DNA by ionising radiation, double-strand breaks (dsb) are
the most closely related to cell death. In support of this,
recent data suggest that differences in radiosensitivity in
rodent cell lines are related to differences in dsb induction
(Radford, Int. J. Radiat. Biol., 49, 611, 1986).
We have investigated the induction of dsb in 3 human
lung carcinoma lines and 3 human cervical carcinoma lines,
of varying sensitivity. Irradiations were performed using
60Co y-rays at a dose rate of 1-1.5 Gymin- and cell
survival measured using monolayer and soft agar clonogenic
assays.
Dsb were measured following irradiation at ice-bath tem-
perature using the neutral filter elution technique (pH 9.6).
No significant differences were seen in dsb induction up to
45 Gy in tumour cell lines with Do 0.88-1.8 Gy. We con-
clude that within the limits of the commonly used neutral
elution assay, induced dsb may not correlate directly with
cell kill in human tumour lines. While this does not invali-
date the idea that dsb may be the lethal lesion following
exposure to ionising radiation, it does suggest that the
processing of these lesions following induction may be the
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Development of resistance in a human bladder cancer cell
line by intermittent exposures to thiotepa
L. Walker"2 & J.R.W. Masters'
'Department of Pathology, The Institute of Urology, London
WC2H9AE; and 2Department of Urology, St Thomas'
Hospital, London SE] 7AE, UK.
ThioTEPA is the agent most frequently used for intravesical
treatment of superficial bladder cancer. One-third of patients
enter complete remission; one-third, partial remission; and a
third do not respond (Lum, Rec. Res. Cancer Res., 85, 3,
1983). Drug resistance, either present at the start of treat-
ment or induced as a result is a major limitation of
intravesical chemotherapy. We induced drug resistance in
vitro, using a human urothelial cancer cell line, MGH-U1. A
single clone was developed and used for these experiments.
Drug response of the clone was measured by clonogenic
assay, to select a concentration that produced 10-20%
clonogenic cell survival after 1 h exposure. Three separate
flasks were then treated by successive 1 h exposures to
40,ugml-' of ThioTEPA. Ten exposures were carried out, at
intervals of at least one week. The medium in three control
flasks was changed in parallel. After 10 exposures, treated
cells, parallel controls, and pre-treatment cells were com-
pared in their response to 40 ugml-' of ThioTEPA for 1 h.
Mean percentage clonogenic cell survival was 22.2% + 5.88
(s.d.) for pretreatment cells; 23.7% +7.22 for parallel
controls; and 43.3% +3.16 for treated cells. The resistant cells
are now being characterised in terms of isozyme phenotype,
growth rates, and morphology.
The data indicate that 2 fold resistance was induced in a
human urothelial cancer cell line by a regime of ThioTEPA
treatment modelled on a course of intravesical
chemotherapy.
Evidence for 06-alkylguanine DNA alkyltransferase gene
amplification in chloroethylating agent selected Chinese
hamster lung fibroblasts
J.E.N. Morten & G.P. Margison
Paterson Institute for Cancer Research, Christie Hospital,
Manchester M209BX and ICI Diagnostics Group, Gadbrook
Park, Northwich, Cheshire CW9 7RA, UK.
Chinese hamster V79 cells are very sensitive to the toxic
effects of chloroethylating agents such as mitozolomide
(Mz). The specific activity of 06-alkylguanine-DNA-alkyl-
transferase (ATase) in extracts of such cells is < fmolmg-'
protein. In order to examine the extent to which Mz
resistant cells within the population expressed higher levels
of ATase, cells surviving Mz treatment were expanded and
extracts of the cells were assayed for ATase activity. The
resistant population was then exposed to a higher dose of
Mz and the expansion and selection process repeated with
incrementally increasing doses of Mz. ATase activity was
found to increase with increasing selection dose and has so
far attained >300 fmolmg- I protein at a dose of
100Mgml-' Mz. No evidence of alkylphosphotriester ATase
activity was found in extracts of these cells. The karyotype
and DNA fingerprint of the selected population confirmed
that they were derived from the parent cells. Double minute
chromosomes were observed in Mz-selected cells. These
increased in frequency with increasing selection dose and an
average of 3 per cell occur in cells surviving 120,ugml- Mz.
The stepwise increase in ATase specific activity and the
occurrence of double minute chromosomes are consistent
with ATase gene amplification.
Regulation of glutathione S-transferases in rat liver by
exogenous compounds
C. Dolan" 2, C.R. Wolf2 & J.D. Hayes1
'Department of Clinical Chemistry, Royal Infirmary,
Edinburgh; and 2ICRF Laboratory of Mol. Pharmacol.,
Department of Biochemistry, University of Edinburgh,
Edinburgh, UK.
Changes in the cellular levels of glutathione transferase
(GST) enzymes appear to play an important role in preneo-
plasia and in the resistance of tumour cells to cytotoxic
drugs. It is therefore important to understand the factors
which regulate the levels of these compounds within cells. To
this end we are studying GST regulation by both exogenous
and endogenous compounds. Treatment of rats with pheno-
barbital (PB) and 3-methylcholanthrene (3-MC) leads to
significant induction of hepatic Ya/Yc and Yb mRNA levels.
As these compounds also induce cytochrome P-450, a multi-
enzyme system involved in foreign compound metabolism,
we have looked at the effect of a wide range of cytochrome
P-450 inducing agents on GST mRNA levels in rat liver. The
compounds used and their relative effect are given below:
Inducing agent
GST
subunit AF 2AAF ETOH PB DEX
Ya/Yc ++ ++ NC ++++ ++++
Yf NC NC NC NC II
Yb ++ ++ NC ++ ++
GST
subunit ARO BA aNF PNF CLO
Ya/Yc ++++ ++ + +++ NC
Yf NC NC NC ++ NC
Yb ++ + ++ ++ +
It can be seen that many of the above compounds cause
very significant changes in the levels of GST mRNA within
rat liver. The Ya/Yc mRNA being regulated in a similar
fashion to the Yb group. Of particular interest is the
induction of the Yf subunit by /NF. This is an enzyme used
as a preneoplastic marker and is associated with drug
resistance. This is the first report of the regulation of this
subunit by an exogenous organic molecule.
Detoxication of peroxidized DNA by human and rat GSH
transferases: Isolation of a form having high activity from
rat liver nuclei
K.H. Tan', D.J. Meyer', N. Gillies2 & B. Ketterer'
'CRC Molecular Toxicology Group, and 2Department of
Oncology, University College and Middlesex School of
Medicine, Cleveland Street, London WIP6DB, UK.
Purified rat and human liver GSH transferases from the
soluble supernatant fraction have activity towards DNA
peroxidized aerobically by ionizing radiation. GSH transfer-
ases 5-5, 3-3 and 4-4 are the most active in the rat (500, 35
and 20 nmolmin-l mg-' respectively) and GSH transferases
, and 7r the most active in man (80 and 10 nmolmin- mg-
I
protein respectively). In rat liver nuclei two GSH transferase
fractions were obtained, one extractable with saline/EDTA
('free') and the other with 8.5M urea ('bound'). The 'free'
fraction contained GSH transferase subunits 1 (40%); 2
(25%); 3 (5%); 4 (5%) and a subunit similar to 5 and
referred to as 5* (25%). The 'bound' fraction contained
principally subunit 5* (95%) and a small amount of subunit
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was also active towards peroxidized DNA, but since it
accounts for only 20% of the free GSH peroxidase activity
in the nucleus, GSH transferases may be more important.
The results implicate a role for GSH peroxidases in DNA
repair.
Glutathione transferase isoenzymes in normal and neoplastic
bladder tissue
J. Carmichael', A.L. Harris', K. Smith', D. Neal',
J.D. Hayes, L.M Forrester', M. Glancy' & C.P. Wolf'
1University Department of Clinical Oncology and Urology,
Newcastle upon Tyne; 'Department of Clinical Chemistry,
Royal Infirmary, Edinburgh; and 'ICRF Laboratory of
Clinical Pharmacology and Drug Metabolism, Edinburgh,
UK.
The glutathione transferases (GST) represent a multigene
family of isoenzymes which are important in the handling of
xenobiotics including many cytotoxic drugs. They have been
implicated in the development of drug resistance, and in
addition increased levels of GSTs have been observed in
pre-neoplastic states. Three main groups have been identified
based on their separation by isoelectric focussing. GST
isoenzyme activity was estimated in 32 human bladder
samples: 16 invasive carcinomas, 12 superficial carcinomas
and 4 normal samples. GST isoenzyme activity was esti-
mated with the use of model substrates, chlorodinitrobenzene
(CDNB) for overall activity, ethacrynic acid (EA) for the
acidic forms and cumene hydroperoxide (CuH202) as an
estimation of basic enzymes. A selection of these samples
were further analysed by Western blotting, using antisera to
3 human GSTs. Mean CDNB activity in invasive tumour
tissues was 163 (range 50-588), in superficial tumours 380
(26-802) and normal tissue 163 (128-236) nmol CDNB
conjugated min-'mg-' protein. There was an increase in
CuH202 activity in selected tumours, but no difference with
the acidic forms as determined using EA. Western blotting
showed that the acidic isoenzymes were present at highest
concentration and were present in all samples. A few tumour
samples exhibited basic subunits with no significant neutral
activity observed. Thus interesting differences in expression
of GST isoenzymes were observed in superficial bladder
tumours, although it should be emphasised that wide inter-
individual variation in levels was observed. Acidic transfer-
ases were present in the greatest concentration as has
previously been found in lung cancer samples. Basic activity
was observed in some tumour samples, with minimal activity
in normal tissue, and virtually no neutral isoenzymes seen.
a-Interferon in combination with cytotoxic drugs against
human lung carcinoma cell lines
R.J. Fergusson, S.P. Langdon, M.M. Hawkes & J.F.
Smyth
ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, UK.
Recent studies of ac-interferon (IFN) in combination with
certain cytotoxic drugs have indicated synergistic antitumour
effects against human xenograft models in immune-deprived
mice. This has been demonstrated for cis-platinum
(CDDP)+IFN against human non-small cell lung carcinomas
(NSCLC) (Carmichael et al., Cancer Res., 46, 4916, 1986)
and for adriamycin (ADR)+IFN against a human breast
tumour (Balkwill et al., Cancer Res., 44, 904, 1984).
CDDP+IFN is currently under clinical assessment for the
treatment of human NSCLC.
To investigate further the interaction between cytotoxic
agents and IFN, we have studied the combinations of
CDDP+IFN and ADR+IFN against human lung adeno-
carcinoma cell lines H23, H125 and A549 in vitro. Cells were
plated on plastic at appropriate cell numbers in
RPMI 1640+10% FCS. After 24h, drugs were added for
either 24h or for 5 days. After 7 days colonies were counted.
IC,o values for the 3 cell lines were >105UmI- for 24h
IFN; 102-10 UmP-' for 5 day IFN; 0.5-1.5pM for 24h
CDDP; 25-80 nM for 5 day CDDP; amd 30-50 nM for 24h
ADR. All combinations of CDDP+IFN and ADR+IFN
over either a 24h or 5 day schedule were additive against the
three cell lines when assessed by Steel's isobologram method
(Steel, Int. J. Rad. Onc. Biol. Phys., 5, 85, 1979). Further
studies are in progress examining these combinations in vitro
against lung models where synergy has already been demon-
strated in vivo.
Phenotypic changes induced in lung adenocarcinoma cell
lines by sodium butyrate
S.P. Langdon, M.M. Hawkes, F.G. Hay & J.F. Smyth
ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, UK.
We have examined the effects of sodium butyrate (SB), an
agent capable of inducing differentiation in many systems,
against 3 human lung adenocarcinoma cell lines (H23, H125
and the alveolar line A549). It has recently been shown that
the monoclonal antibodies (MoAbs) 123C3 and 123A8,
raised against a small cell lung carcinoma (SCLC), react with
approximately 100% SCLC (25/25 positive) but are generally
unreactive with lung adenocarcinoma sections (1/27 positive)
(D. Schol et al., Br. J. Cancer, 56, 519, 1987). SB induced
both these markers in these cell lines (Table below) after 4
days exposure at cytostatic doses (>3mM). Alkaline phos-
phatase was also induced in these cells at these doses
(Table). These phenotypes were determined by (immuno-)
histochemical staining.
% Cells +ve
A549 H23
Phenotype 0mM 3mM 5mM OmM 3mM 5mM
123C3 0 55 68 0 31 35
123A8 0 63 64 0 60 38
Alk Phos 2 51 51 1 9 38
H125
Phenotype 0mM 3mM 5mM
123C3 0 75 98
123A8 0 63 93
Alk Phos 1 27 36
Both 123C3 and 123A8 are members of a group of 11
MoAbs (defined as Cluster 1) active against SCLC which
show strong neural activity (R.L. Souhami et al., Lancet,
8554, 325, 1987). Other members of Cluster 1 were not
induced in these cell lines after exposure to SB. The effect of
SB on other possible differentiation markers in these cell
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Oestrogen receptor expression and effects of tamoxifen
against human ovarian carcinoma cell lines
M.M. Hawkes', S.P. Langdon', S.S. Lawrie', R.A.
Hawkins2, A. McDonald', A. Tesdale2 & J.F. Smyth'
1ICRF Medical Oncology Unit, Western General Hospital
and 2University Department of Surgery, Royal Infirmary,
Edinburgh, UK.
A number of clinical studies have examined the role of anti-
oestrogen (E) therapy for ovarian cancer. While over 50%
ovarian tumours possess oestrogen receptors (ER), clinical
response rates with the anti-oestrogen tamoxifen (T) are
reported to be between 0 and 36%. To assess the importance
of ER for growth and as a possible target for therapy in this
disease, we have examined the effects of T against a series of
8 ovarian cancer cell lines. The ER content of the cell lines
was determined by a dextran-charcoal adsorption assay. The
series of cell lines PEOl, PEO4 and PEO6 possessed high
values of ER (60-200fmolmg-1 protein), PEAl and PEA2
had low values (I0-30fmolmg-1) and PEO14, TO14,
PE023 were ER-ve. Examination of different passages of
PEO4 cells indicated that ER values increased with passage
number for this cell line. All 8 cell lines were relatively
insensitive to the effects of T. ICSO values of the cell lines in
a colony forming assay on plastic were all 8 pM for a 72 h
exposure to T, independent of their ER status. Doses of
>8 MM T (over 7 days) were cytostatic to all lines (cf. breast
ca cell lines sensitive at doses of < 1MM). The ER+ve line
PEO4 grew more rapidly in the presence of added E and
more slowly on removal of E.
Vimentin expression (VE) has been suggested to be an
indicator of progression to hormone-independence in a
hormone-dependent malignancy (Agnor et al., Proc. AACR,
28, 11, 1987). For these 8 cell lines an inverse correlation
was found between ER and VE.
An in vitro assay of cell viability based on staining fixed
cells with alcian blue
J.A. Hanson, E.A. Bean & J.L. Moore
Radiation Sciences Laboratories, Velindre Hospital, Cardiff,
UK.
The differential staining of cells with a vital dye can be
carried out on fixed cells (Yip & Auersperg, In Vitro, 7, 323,
1972). This finding along with the publication of the 'DiSc'
assay for determining in vitro chemosensitivity of haemato-
logical malignancies (Bird et al, Leukemia Res., 10, 445,
1986) caused us to consider the possible use of an alcian blue
based dye exclusion assay on previously fixed cells.
Following treatment cells (Molt4 and Daudi) were cul-
tured for 4 days when they were fixed in glutaraldehyde in
phosphate buffer. They were left in iced water for 1 h and
subsequently at 4°C. The samples were stained with alcian blue
including duck red cells (internal standard) and slides
prepared using a cytospin centrifuge. We found that with cell
lines counterstaining was unnecessary and slides could be
rapidly prepared by dehydrating in ethanol followed by
clearing in xylene and mounting with Canada balsam. Where
counterstaining was required we used Giemsa followed by
the above procedure.
Using two cell lines we have obtained dose response
curves following radiation and drug (Adriamycin and AraC)
exposure in our dye exclusion assay, a soft agar clonogenic
and MTT assay. We consider this ability to fix cells for
examination/processing at a later date to be of general use.
It is also preferable to deal with fixed samples where
possible. For the specific application of in vitro viability
studies, it is limited to suspension cultures as clumping may
be a practical problem for other cell types. A pilot study
with CLL samples to assess cell/drug response is currently
in progress.
Establishment and characterisation of small cell lung cancer
cell lines
R. Milroy', J. Plumb', W. Candlish3, M.R. Adamson3,
S.W. Banham2 & S.B. KayeI
'Departments of Medical Oncology, University of Glasgow;
and Departments of 2Respiratory Medicine and 3Pathology,
Royal Infirmary, Glasgow, UK.
Small cell lung cancer (SCLC) is usually chemoresponsive at
outset but relapse is a frequent occurrence. Such relapse
tumour is often chemoresistant. Comparison of cell lines
derived from pre-treatment and from relapse tumours may
give an insight into the mechanisms of drug resistance. Thus,
we have successfully established five SCLC cell lines in vitro
from 17 biopsies (1/7 bronchial biopsies taken via the
fibre-optic bronchoscope and 4/10 metastases). Three pre-
treatment lines have been established from: (a) an endobron-
chial biopsy from a subsequently chemoresistant patient
(LS106), (b) a metastatic node deposit from a subsequently
chemosensitive patient (LSII1) and (c) a cutaneous metasta-
sis from an untreated patient (LS112). Two further cell lines
of biopsies obtained from a patient who relapsed twice
following chemotherapy have been established following
passage in athymic nude mice. These lines grow as floating
aggregates of cells in RPMI 1640 culture medium supple-
mented with FBS (2.5%), selenium, insulin and transferrin.
A sub-line of LSI 12 grows as a monolayer culture in
Waymouth's medium containing FBS (10%). The lines show
features of human SCLC on pathological examination,
express NSE and CAM 5.2 and contain both dopa-
decarboxylase and creatine kinase (BB) activities. Chemo-
sensitivities were measured in these cell lines by an assay
based on the reduction of a tetrazolium dye, MTT. We
found that the cell lines demonstrate a wide range of
chemosensitivities to adriamycin (10-8 to 10-7M) and this
suggests that they will prove useful models in the study of
drug resistance in vitro.
Effect of Tween80 on the disposition of thioTEPA given
intravesically
B.J. McDermott', J.R.W. Masters2, P.J.R. Shah2, E.
Fenwick2, P.M. Loadman3 & M.C. Bibby3
'Department of Therapeutics and Pharmacology, The
Queen's University of Belfast; 2Institute of Urology,
University College London; and 3Clinical Oncology Unit,
University of Bradford, UK.
The uptake of a number of chemotherapeutic agents and
their cytotoxicity are enhanced by Tween80 in vitro and in
vivo. Added to ThioTEPA, the non-ionic detergent signifi-
cantly reduced the colony-forming ability of a human
bladder cancer cell line (Parris et al., Urol Res., 15, 17,
1987). Therefore, this combination might be more effective
than drug alone for intravesical chemotherapy of superficial
bladder cancer, although Tween80 could increase the sys-
temic absorption of ThioTEPA and so potentiate its myelo-
suppressive effects. A pharmacokinetic study using a
randomised cross-over design was performed in which 8
patients with multiple recurrent stage pTa or pTI disease
were given ThioTEPA (30mg) in distilled water or in 10%
(v/v) Tween80 (30ml) for 2h, followed 3 months later by
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proportion of ThioTEPA absorbed (20-78%), but the rate of
absorption was not affected by Tween 80. Peak plasma
levels, 101 and 154ngml-1, were observed within 1 h of
administration, concentrations fell with half-lives of 1.83 and
1.25 h and AUC values were 0.376 and 0.496 pg hml- I with
drug alone and in combination with Tween 80 respectively:
the difference between these mean values were all significant
(P<0.05). These results indicate an apparent reduction in
the volume of distribution of ThioTEPA when administered
with Tween 80. WBC count decreased significantly 14 days
following treatment only after the therapy including
Tween 80. It is concluded that the maximum safe dosage
would be considerably less than that with drug alone if
Tween 80 were added to intravesical chemotherapy with
ThioTEPA.
A phase I-II study of ifosfamide in combination with
adriamycin in the treatment of adult soft tissue sarcoma
J.L. Mansi, S. MacMillan, C. Fisher & E. Wiltshaw
The Sarcoma Unit, The Royal Marsden Hospital, Fulham
Road, London SW3 6JJ, UK.
To evaluate the two most active drugs in the treatment of
soft tissue sarcomas 54 patients were treated with a combi-
nation of ifosfamide and adriamycin at a dose of 5 gm-2
and at least 40mgm-2 respectively at 3 weekly intervals. Of
the 50 evaluable patients a response was seen in 11 (22%)
patients (3 complete responses and 8 partial responses),
stabilisation of disease occurred in 17 patients and the
remaining 22 patients progressed whilst on treatment. Of the
22 patients receiving adriamycin at 60mgm-2 12 (55%)
required a dose reduction due to toxicity compared to 11
(39%) of the 28 patients who received 40mgm-2. For the
patients who had a response the median relapse-free interval
was 7 months (range 2-17+) and the overall median survival
was 12 months (range 5-29+). The combination does not
appear to increase the response rate above that of single
agent chemotherapy.
Guanidibenzoatase activity of tumour cells and the regulation
of tumour invasion
F.S. Steven', M.M. Griffin1 & H. Maier2
'Department of Biochemistry and Molecular Biology,
University of Manchester, Manchester M139PT, UK;
2E.N.T. Clinic, Justus-Liebig University, Gissen, FRG.
We have examined 55 tumour bearing tissues taken from the
head and neck regions as frozen sections. We employed 9-
aminoacridine as a fluorescent probe for cells possessing the
tumour associated protease guanidinobenzoatase. We
observed that most of the cells within the tumour masses in
these sections did not bind 9-aminoacridine and therefore
possessed inhibited enzyme which was subsequently exposed
by displacement of the inhibitor. We noted that the cells at
the advancing edge of the tumour masses and individual
tumour cells in the stroma bound 9-aminoacridine and
fluoresced. Guanidinobenzoatase is known to degrade fibro-
nectin and we believe that those cells possessing uninhibited
guanidinobenzoatase in vivo are capable of migration and
tissue invasion. We observed that guanidinobenzoatase in
solution and on the surface of these fluorescent tumour cells
was inhibited by 10-6 M bis-(carbobenzoxy-arginine)-
rhodamine in an irreversible manner. This synthetic inhibitor
had no action on trypsin or cell-bound guanidinobenzoatase
which was already complexed with the normal inhibitor in
these frozen sections. We conclude that the activity of
tumour cell guanidinobenzoatase is regulated in vivo by the
naturally occurring inhibitors. Only those cells at the advan-
cing edge of the tumour mass possessed active enzyme and
this could be selectively inhibited by a synthetic arginine
derivative.
Provisional assignment of ecto-5'-nucleotidase to human
chromosome 6
Y. Hey, M. Fox & J.M. Boyle
Paterson Institute for Cancer Research, Christie Hospital
and Holt Radium Institute, Manchester M209BX, UK.
Ecto-5'-nucleotidase (5'-NT) is a glycosylated protein consist-
ing of a dimer of subunit 70 kD bound by glycosyl phospha-
tidyl inositol linkage to the external plasma membrane of
mammalian cells and to microsome and Golgi membranes.
The enzyme converts 5' purine nucleotides to nucleosides,
AMP being the preferred substrate. Specific activity increases
during differentiation of B and T cells and consequently the
enzyme is used as a marker to distinguish differentiation
arrested leukaemias (low 5'-NT e.g. T-acute lymphoblastic
leukaemia) from end cell leukaemias (high 5'-NT, common
acute lymphocytic leukaemia and blast crisis in chronic
myelogenous leukaemia). Elevated 5'-NT has also been
observed in cells resistant to purine analogues.
Using a panel of 26 human x hamster hybrids and a rapid
assay of 5'-NT on whole cells we observed 92% concordance
of 5'-NT with the presence of human chromosome 6. The
2/26 discordant cell lines were subsequently shown to have
been erroneously karyotyped with respect to chromosome 6.
The HLA Class I genes are carried on human 6p and the
Class I antigen is recognised by the murine monoclonal
antibody W6/32. Human x hamster hybrids that contain
chromosome 6 fluoresce weakly when stained with W6/32
and rabbit anti-mouse FITC enabling HLA+ and HLA-
cells to be sorted by FACS and cloned. In all hybrids and
segregants tested there was 100% concordance in the expres-
sion of HLA+ 5'-NT+ confirming the linkage of a gene
controlling 5'-NT expression to human 6.
Lectin-binding affinities in human primary breast tumours
and axillary lymph node metastases
D.T. Risnit
Institute of Oncology, Department of Immunochemistry,
3400 Cluj-Napoca, Romania
The role of carbohydrate structures of the cell membrane
surface in immunogenicity, cell adhesion and proliferation is
well known. Using several fluorescein- or horseradish peroxi-
dase-labelled lectins, we and others have demonstrated their
binding in breast carcinoma cells. Recently (Leathem &
Brooks, Lancet, 8541, 1054, 1987) the binding of Helix
Pomatia (HPA) has been shown to have some value in
prognosis. In this study we used a panel of peroxidase-
conjugated lectins (ConA, WGA, SBA). On paraffin-
embedded sections obtained from 30 primary breast tumours
and from their axillary lymph node metastases respectively,
we analyzed the difference in lectin-binding between primary
tumour and its metastases as well as the significance of this
difference. Computerized image analysis was used to evalu-
ate the intensity of positive staining. At the level of the
malignant breast, cell membrane alterations were present
which allowed specific lectin binding. In some cases this
binding had different patterns and was more intense in
metastases than in the corresponding primary tumours,
suggesting well-marked alterations of cell-surface carbo-
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useful in micrometastasis identification, may allow us to gain
further insight into an understanding of the metastatic
process.
An inducible clonal marker system to investigate mutations
and clonal organisation in gut epithelia
B.A.J. Ponder, M.A. Blount & D.J. Winton
Institute of Cancer Research, Haddow Laboratories, Clifton
Avenue, Sutton, SurreySM25PX, UK.
C57BL/6J (B6) mice express a binding site for Dolichos
biflorus agglutinin (DBA) on gut epithelium, SWR mice do
not. This difference is specified by alleles at a single locus.
DBA binding is dominant; thus B6 x SWR Fl mice possess a
single allele which determines DBA binding, and the gut
epithelium of these Fl mice can be stained in whole mounts
using DBA-peroxidase conjugate. In animals killed 2 weeks
after a single dose of the mutagen ethylnitrosurea (ENU),
however, negatively staining ribbons of epithelial cells are
seen arising from the gut floor and ascending to the tips of
the villi. We interpret these as clones originating from
mutated crypt stem cells which have lost the DBA binding
allele. The evidence for this is: (1) the putative clonal
patterns are similar to those we have previously described in
B6*-+SWR chimaeric intestine; (2) the DBA -ve clonal
patterns can be initiated during foetal development and
persist as 'descendent clones' in the adult; (3) no DBA -ve
clones are seen in homozygous DBA +ve B6 control mice;
(4) a dose-response relationship is observed with increasing
doses of ENU; and (5) the number of events observed (e.g.
20-30 per 104 villi 2 weeks after a single dose of
ENU 50 mgkg-1) are consistent with somatic mutation. Par-
tially or wholly mutated intestinal crypts can also be scored
in whole mounts of small intestine and colon. This novel
technique can be used to investigate the clonal organisation
of the crypt and the occurrence and persistence of 'spon-
taneous' or induced mutations at different levels of the crypt
stem cell hierarchy under different conditions.
The possible use of serum NMHC class II levels for
monitoring graft-versus-host disease in bone-marrow
transplant recipients
S. Thompson', M. Wareham1, A.D.J. Pearson2,
L. Sviland2 & G.A. Turner'
Departments of 'Clinical Biochemistry and 2Child Health,
The Medical School, Framlington Place, Newcastle upon
Tyne NE24HH, UK.
Bone-marrow transplantation (BMT) is increasingly being
used to treat leukemias and lymphomas. Detection of graft-
versus-host disease (GVHD) in these patients is a difficult
and time-consuming task that requires intensive patient
investigation. As HLA Dr is expressed on keratinocytes and
enterocytes in GVHD (Sviland et al., Bone Marrow Transpl.,
3, 408, 1987), measurement of blood levels of class II
molecules could form the basis for a new test for monitoring
GVHD. Class II levels were measured in sera from healthy
individuals and from 26 patients who received either an
allogeneic or an autologous BMT as part of their therapy.
Specimens from the latter group were taken prior to
transplantation (A) between one and four weeks after
treatment (B) and on two further occasions up to 6 months
later (C, D). In 20% of specimens it was impossible to
measure class II levels because of interference by rheumatoid
factors. Although insufficient serial specimens were available
for many of the patients, certain preliminary observations
can be made. Class II molecules were detectable in 6/22
healthy individuals (mean-0.49 Uml-1) and 17/26 group A
patients (mean=2.32 Uml-1) and these groups were
significantly different (P=0.002). Following grafting, class II
levels increased further in 12/15 patients (A vs. B, P<0.05).
At later times (C and D), levels changed according to the
type of graft. With autologous grafts and allogeneic grafts
without GVHD (7 patients), levels progressively decreased to
values similar to or less than those in group A. In 4 patients
with GVHD following allogeneic BMT, levels tended to
remain elevated. It is concluded that measurement of serum
class II levels may be useful for monitoring GVHD but
further work is needed to establish this approach.
Lack of free-radical formation by a doxorubicin-oestrogen
conjugate
N.G. Hartman', L.H. Patterson2, A. Suarato3,
F. Angelucci3, P. Workman1 & F. Arcamone3
1Cambridge University Department of Clinical Oncology and
Radiotherapeutics, Cambridge CB22QQ; 2School of
Pharmacy, Leicester Polytechnic, Leicester LE] 9BH, UK;
3Farmitalia Carlo Erba, Milano, Italy.
Drug-targeting provides a means to reduce drug toxicity.
Increased expression of oestrogen receptors on mammary
tumour cells affords a tumour-specific drug-targeting stra-
tegy. The cardiac toxicity of the anthracyclines could be due
to free-radical generation. We have synthesized a novel
oestrone carboxymethoxylamine doxorubicin conjugate and
evaluated its capability to generate such toxic species, using
rat liver microsomes, in comparison with parent doxorubicin.
The oestrogen conjugate had a minimal effect on the basal
rate of the liver microsomal NADPH-consumption
(10.7+1.1 nmolmin-1 mg-1 protein); or liver microsomal
superoxide anion generation, determined via acetylated cyto-
chrome c reduction (20.2+0.8 nmolmin 1 mg- I protein), or
adrenochrome formation from adrenaline (30.2+2 nmol-
min- mg protein). In contrast, doxorubicin displayed a
concentration-dependent increase above basal rates for all
these parameters. No esr signal was generated in NADPH-
fortified microsomes when the conjugate was incubated
anaerobically for up to 30min. Under identical conditions an
esr spectrum for the doxorubicin quinone free-radical was
observed, which became more anisotropic with time. In
addition, the conjugate inhibited the free-radical esr spec-
trum of parent doxorubicin. These results suggest that the
oestrone carboxymethoxylamine doxorubicin conjugate is
not metabolically reduced to a free radical intermediate in
rat liver microsomes, thus eliminating this as a mechanism of
toxicity. In addition, the conjugate inhibits the free-radical
formation of doxorubicin, providing a positive guideline
towards future anthracycline development or hormone-drug
combination therapy.
Increase in tumour growth after blood transfusion
P. J. Clarke, K.J. Wood & P.J. Morris
Nuffield Department of Surgery, John Radcliffe Hospital,
Oxford, UK.
There is debate as to whether peri-operative blood trans-
fusion is associated with a poorer prognosis in patients
undergoing tumour resection. The results of retrospective
clinical studies are conflicting and difficult to interpret.
Preliminary experiments in a mouse tumour model indicated
that spontaneous metastases from a subcutaneous primary
were augmented when the animals were transfused with
allogeneic blood 14 days before tumour inoculation. Further
studies have now investigated the effect of both the timing of
the transfusion and the strain of the donor blood.TWENTY-NINTH ANNUAL MEETING OF THE BRITISH ASSOCIATION FOR CANCER RESEARCH 251
Groups of C3H (H2k) mice were transfused with 0.25ml
of C57/B16 (H2b) blood at days -14, -7, 0 and +7 in
relation to an inoculum of UV-2237 fibrosarcoma cells at
day 0. Control groups were transfused with syngeneic blood
at each time point. Animals were all killed at day +21 and
those transfused with allogeneic blood on days -14, -7
and +7 showed a significant increase in the number of
pulmonary tumour deposits compared with controls. This
effect was dependent on the dose of tumour inoculated,
being most marked when the injected dose was near the
minimum dose needed for tumour growth (MTD).
In further experiments, groups of mice were inoculated
with UV-2237 cells and on day +7 were transfused with
blood from donors which varied both at the major and/or
the minor histocompatibility antigen loci. At day +21 the
mice were killed to assess lung colonisation and the results
showed that the augmentation of tumour deposits by blood
transfusion was dependent on the donor strain and suggested
that differences in both major and minor histocompatibility
antigens may be involved.
Use of a monoclonal antibody-mediated haemadsorption
method to identify tumour cell colonies in mixed cultures
M.J. Embleton, K. Affleck & A. Capuano
use of such conjugates to quantitate the rate of uptake is
difficult due to fluorescence quenching by various factors.
Rate of uptake was therefore quantitated using 1251-labelled
antibody.
After binding labelled antibody to cells at saturating
levels, endocytosis was allowed to proceed for various times
at 37°C. Bound non-endocytosed material was removed from
cells by digestion with papain on ice, followed by centri-
fugation. The percent endocytosis compared to material
originally bound at time zero was then calculated by the
following equation:
Percent endocytosis =P,- St xPO/SO x 100/PO+SO
where P=cpm in pellet, S=cpm in supernatant,
subscript 0=time 0 and subscript t= time t.
This equation corrects for bound material not completely
digested from the cell surface.
Use of this assay to quantitative uptake of 1251-791T/36
antibody on 791T cells showed 30% uptake after 4h. The
specificity of uptake was demonstrated by washing cells prior
to endocytosis, but true rates of endocytosis were given by
incubation with antibody throughout the assay. The latter
method showed that uptake was linear for a minimum of
4h, strongly indicative of a pinocytic rather than a receptor-
mediated endocytic process.
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG72RD, UK.
A method involving adherence of monoclonal antibody
(MoAb)-coated sheep red blood cells (SRBC) was developed
to facilitate the identification of adherent colonies growing in
cultures of mixed tumour cells, established for the purpose of
studying cellular interactions. Anti-tumour MoAbs were
purified by affinity chromatography and adjusted to
1 mgml-I in 0.9% w/v sodium chloride without buffers. A
1% w/v solution of chromic chloride was adjusted to pH 5.0
and left to 'age' for at least 3 weeks. SRBC were washed
twice in 0.9% NaCl and spun down, and appropriate
volumes of cell pellet were added to an equal volume of
antibody, followed immediately by addition of CrCl3 while
agitated on a vortex mixer. The SRBC were left for 10min
at 20°C and washed twice in phosphate-buffered saline
(pH 7.2) before resuspension in Eagle's MEM+10% calf
serum. Mixed cultures containing tumour cell colonies were
drained of medium and the MoAb-coated SRBC were
added, followed by 20min incubation at 20°C. The cultures
were then rinsed free of unattached SRBC, fixed in metha-
nol, and stained with Leishman's stain.
Using tumour cell lines and MoAbs of known reactivity, it
was established that MoAb-coated SRBC adsorbed strongly
to colonies of cells bearing the antigen recognised by the
MoAb. SRBC treated with saline or a non-cross-reactive
MoAb did not bind to cell colonies, although the sensitivity
of the assay was such that weak cross-reactions gave a
positive result. By careful matching of MoAbs to the cells
used, this method provides a useful means of identifying
colonies of cells with similar morphology in mixed cultures.
Quantitation of endocytosis of antibody by a radiolabel
method
M.C. Garnett, T.H.A.Y. Huehns, J.R. Martin, C.R.L.
Graves & S.L. Smith
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG72RD, UK.
The endocytosis of 791T/36 antibody has been previously
demonstrated by the use of fluorescent conjugates (Garnett
& Baldwin, Eur. J. Cell Biology, 41, 214, 1986). However,
Radiosensitivity of peripheral blood lymphocytes in
radiotherapy patients
J.O.T. Deeley, J. Marks, I.J. Kerby & J.L. Moore
South Wales Cancer Research Council, Radiation Science
Laboratory, Velindre Hospital, Whitchurch, Cardiff
CF4 7XL, UK.
When the nuclei of human lymphocytes are challenged with
2 M NaCl a histone-free-DNA-protein (HF-DNA) complex is
released (Harris et al., Int. J. Radiat. Biol., 47, 689, 1985;
George et al., Br. J. Cancer, 55, 141, 1987). The sedimen-
tation distance of the HF-DNA complex in a linear sucrose
gradient (pH 8.0) is less when immediately isolated from in
vitro irradiated cells than that when isolated from unirra-
diated cells. Typically, there is a non-linear dose response in
the sedimentation behaviour. At low doses, if irradiated cells
are incubated at 37°C the sedimentation behaviour
approaches that of unirradiated cells ('repair') - generally,
repair is complete after an incubation of 1 h at 37°C.
The repair of irradiated lymphocytes derived from
'healthy' control donors was similar to that of lymphocytes
derived from patients with carcinoma of the uterine cervix
(blood was taken when the patient presented at the first
clinic for radiotherapy). Most donors demonstrated complete
repair following an incubation of 1 h at 37°C. However, 2/28
(7%) controls and 2/25 (8%) patients were repair. deficient
showing a less than 30% repair following incubation. In
addition, the repair of irradiated lymphocytes derived from
patients treated by radiotherapy 2 to 5 years previously for
carcinoma of the uterine cervix has been examined. Of those
now attending with 'bowel complications' attributed to
radiotherapy 7/16 (44%) showed a less than 30% repair. In
contrast, all those (11/11) described as 'well and
complication-free' showed good repair, that is greater than
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The activation of CB1954 (2,4-dinitro-5-aziridinyl benzamide)
in Walker cells is by bioreduction to a DNA crosslinking
agent
R.J. Knox, F. Friedlos & J.J. Roberts
Institute of Cancer Research, Sutton, Surrey, SM25PX,
UK.
Walker tumour cells were shown to be highly sensitive to the
cytotoxic effects of the compound CB 1954, a monofunctio-
nal alkylating agent, when compared with other cells in vitro.
However CB 1954 forms DNA-DNA inter-strand crosslinks
(as determined by alkaline sucrose gradient sedimentation
analysis) in a time-dependent manner in Walker tumour cells
but not in V79 cells, which are not sensitive to this agent.
The absence of inter-strand crosslinks in hamster cells was
not due to a lack of uptake of the drug but rather to their
failure to convert (probably by bioreduction) CB 1954 to a
difunctional intermediate, the mechanism for which has now
been identified in Walker cells. As Walker cells are at least
10,000 fold more sensitive, on a dose basis, than are hamster
cells it is of considerable interest to determine if some human
tumour cells are also capable of activating, or can be made
to activate CB 1954 to a difunctional agent.
Independent action of radiation and platinum compounds on
human foetal lung cells in vitro and human melanoma cells
in vivo
Of the 28 patients, 12 had a positive cytological diagnosis of
malignancy. The effusions from these affected patients were
found to have a mean total TK level of
4681.5 +725.0 cmpml 1 min-1. Patients in whom malignancy
was not diagnosed had a mean total TK activity of
4371.1 +787.4cpmml 1min-1. TK exists in two forms, TK1
and TK2, which can be distinguished on the basis of
phosphate donor specificity. Both TK1 and TK2 can utilize
ATP as phosphate donor. TK1 can utilize CTP as phosphate
donor with approximately 15% the efficiency found with
ATP. TK2 can utilize CTP as phosphate donor with approx-
imately 80% the efficiency found with ATP. The patients
with a positive diagnosis of malignancy were found to have a
mean TK activity, using CTP as phosphate donor, of
1480.7+307.4 cpmml-1 min-1. Patients with a negative cyto-
logical diagnosis had a mean (CTP) TK activity of
2781.3 +391.1 cpmml -1 min-1. The two groups were signifi-
cantly different in this regard (P<0.05). When the two
groups were compared for percent CTP/ATP TK activity the
patients with a positive cytological diagnosis for malignancy
had a mean value of 35.97+5.95%, while patients with a
negative cytological diagnosis for malignancy had a mean
percent CTP/ATP TK activity of 66.15+3.6%. The two
groups were significantly different in this regard (P<0.001).
These results indicate that pleural effusions from patients
with lung cancer may have increased TK1 levels and de-
creased TK2 levels relative to patients without malignancy.
Measurement of TK levels may be a useful adjunct to
cytological diagnosis for malignancy in pleural effusions.
C. Basham1, J. Mills', E.B. Douple2 & J.J. Roberts1
'Institute of Cancer Research, Sutton, Surrey, SM25PX,
UK; 2Dartmouth-Hitchcock Medical Center, Hanover, NH,
USA.
Confluent (stationary phase) human foetal lung cells recover
from damage induced by either radiation or cis-platin but
with different kinetics, that from radiation being maximal
after 2 days, irrespective of the initial dose, while that from
cis-platin was continuous for up to 10 days. At late times
after treatment of cells with a combination of the two agents
the cells exhibited a toxic response equal to the sum of that
produced by either agent alone. Irradiation of exponentially
growing human foetal lung cells before, during or following
a 1 h pulse treatment with cis-platin also resulted in a toxic
effect equal to the sum of that produced by either agent
alone. CBA nude mice implanted with a human melanoma
were either irradiated (12.5 Gy), injected with carboplatin
(100mgkg-1) or injected with carboplatin 45min before
irradiation. The effect of these treatments on the survival of
tumour cells was determined by their colony-forming ability
in vitro I h later. The combination of carboplatin and
radiation produced an effect on cell survival equal to the
sum of the two separate treatments. Thus radiation and
platinum compounds act independently on both normal and
tumour human cells, a finding which suggests a common
mechanism of action and accounts for the beneficial thera-
peutic effects obtained when they are used in combination.
The combined use of the tumour antigens CEA, CAl9-9 and
CA50 in discrimination of oesophagogastric carcinomas
M. Lucarotti, S. Kelly, N.A. Habib, D.J. Leaper, M.
Hershman, R.C.N. Williamson & C. Wood
University Departments of Surgery, Bristol Royal Infirmary,
Bristol and Royal Postgraduate Medical School,
Hammersmith Hospital, London, UK.
The tumour-associated antigens CEA, CA19-9 and CAS0
defined by monoclonal antibodies have been raised against
human colorectal adenocarcinoma cell lines. The aim of this
study was to assess their combined use to identify patients
with oesophagogastric carcinoma.
An immunoradiometric assay was used for the detection
of CEA and CA19-9 and the Delfia system was used for
CA50. Serum was collected from 50 control patients (of
whom 23 had benign upper gastrointestinal disease and 27
were normal subjects) and 23 patients with oesophagogastric
carcinoma. The 'cut-off' discriminant levels for CEA, CA19-
9 and CA50 were 5.4ngml 1, 33.2 Uml 1 and 35.5 Uml -
respectively.
The combination of antibodies was positive in only 1 (2%)
of the control group and 16 of 23 (70%) with oesophago-
gastric carcinoma (Table).
Thymidine kinase activities in pleural effusions
G.B. Nevin', K.L. O'Neill2 & P.G. McKenna2
1Biomedical Sciences Research Centre, University of Ulster,
Newtownabbey BT37OQB; 2Biomedical Sciences Research
Centre, University of Ulster, Coleraine BT52 iSA, UK.
The levels of the nucleotide salvage pathway enzyme thymi-
dine kinase (TK), were assayed in the pleural effusions of 28
patients undergoing cytological examination for lung cancer.
Antibody % Positive in patients with oesophagogastric carcinomas
CEA
CAl9-9
CA50
Combined
35
52
35
70
A combination of all three tumour markers may help to
identify oesophagogastric malignancy and could be useful in
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The clinical use of CA19-9 in the differential diagnosis of
benign and malignant disease of the gastrointestinal tract
M. Lucarotti, S. Kelly, N.A. Habib, D.J. Leaper, M.
Hershman, R.C.N. Williamson & C. Wood
University Departments of Surgery, Bristol Royal Infirmary,
Bristol; and Royal Postgraduate Medical School,
Hammersmith Hospital, London, UK.
CAl9-9 is a tumour-associated carbohydrate antigen from a
human colorectal adenocarcinoma cell line. This study inves-
tigated the role of CA19-9 in the separation of benign from
malignant gastrointestinal disease.
Serum was collected from 50 control patients, 53 with
benign gastrointestinal disease and 136 patients with carcin-
oma of the gastrointestinal tract. An immunoradiometric
assay (CIS UK) was used to detect CA19-9 in the serum and
a level of 33 Uml1 was used as a 'cut-off' to distinguish
between benign and malignant disease.
Serum levels in 10 of the 53 patients (19%) with benign
disease, 20 of 33 (61%) with upper gastrointestinal carci-
noma and 28 of 103 (27%) with colonic carcinoma had
levels above 33 Uml1 (Table).
Carcinoma type No. patients % +ve CA19-9
Pancreatic
Oesophagogastric
Colonic
10
23
103
90
52
25
Therefore CA19-19 may be of help in distinguishing benign
from malignant disease of the upper gastrointestinal tract
but does not help recognise colonic carcinoma.
Predicting response to combined pre-operative radiotherapy
and surgery in rectal cancer
D.J. Jones' 3, J. Zaloudik3, R.D. James2, M. Moore3 &
P.F. Schofield1
Departments of 'Surgery and 2Radiotherapy; and 3Paterson
Institute for Cancer Research, Christie Hospital, Manchester
M20 9BX, UK.
Local recurrence after resection of rectal carcinomas is
reduced by pre-operative radiotherapy and factors which
predict response to radiotherapy could help with patient
selection. Flow cytometric DNA ploidy status is related to
prognosis in colorectal cancer (Jones et al., Br. J. Surg., 75,
28, 1988) and has been evaluated in relationship to response
to radiotherapy in 185 patients with rectal cancer. Ninety-six
were randomised to surgery alone, and 89 to pre-operative
radiotherapy (2,000cGy, over 4 days) and surgery.
DNA aneuploidy was detected in the resected specimens of
59 (61%) patients treated by surgery alone, but in only 33
(37%) after radiotherapy (X2= 11.23, P<0.001). DNA
aneuploidy was detected in 30/44 (68%) pre-radiotherapy
biopsies but in only 15/44 (34%) of these tumours after
radiotherapy.
Preliminary follow-up data show a possible recurrence free
survival advantage for patients in the radiotherapy group
(P=0.07). Patients with DNA diploid tumours had a recur-
rence free survival advantage (P=0.052), but this was con-
fined to the surgery only group. In the radiotherapy group
recurrence free survival rates for diploid and aneuploid
tumours were similar and comparable to those for diploid
tumours in the surgery only group. These preliminary data
suggest the improved recurrence free survival after radio-
therapy is mainly confined to patients with DNA aneuploid
tumours.
Patterns of epithelial cell proliferation of colorectal mucosa
in normal subjects and in patients with large bowel tumours
M. Ponz de Leon, L. Roncucci, C. Sacchetti,
P. Di Donato & L. Tassi
Istituto di Patologia Medica, Policlinico di Modena, 41100
Modena, Italy.
In order to define the predictive and discriminatory value of
autoradiography we evaluated epithelial cell proliferation in
different large bowel segments of subjects with a negative
pancolonscopy and in rectal mucosa of patients with adeno-
matous polyps or cancer. Samples of colorectal mucosa were
taken during endoscopy at - IOcm from the anal verge. In
controls, samples were also taken in caecum, ascending,
transverse, descending and sigmoid colon. After standard
autoradiography and histological preparation, each intestinal
hemicrypt was divided into 5 longitudinal compartments
from the base (comp. 1) to the surface (comp. 5) and
labelled cells (S phase of the replicative cycle) in each
compartment were counted. In controls, total Labelling
Index (LI=ratio of labelled to total cells) and LI per crypt
compartment (ratio of labelled to total cells in each compart-
ment) did not show any significant difference among the
various large bowel tracts. Total LI was higher in patients
with colorectal neoplasms than in controls (but not signifi-
cantly). In contrast, LI per crypt compartment in the most
superficial parts of the crypt (comp. 3-5) was significantly
(P<0.01 at least) higher in the two groups of patients than
in controls. In the fifth compartment labelled cells were seen
in only 15.8% of controls but in 71% and 87.5% of polyps
and cancer patients. In conclusion, in controls cell prolif-
eration was similar in the various large bowel segments, thus
the rectum seems representative of the entire large bowel. In
patients with colorectal tumours an upward expansion of the
proliferative zone was observed; labelling of compartment 5
showed the highest discriminatory power between subjects
with or without intestinal neoplasms.
Increased thrombin activity in patients with small cell lung
cancer
R. Milroy', J.T. Douglas2, J. Campbell', R. Carter1,
G.D.O. Lowe2 & S.W. Banhami
1Department of Respiratory Medicine, and 2University
Department of Medicine, Royal Infirmary, Glasgow, UK.
Abnormalities of haemostasis have been extensively reported
in cancer patients. However, their relationship to response to
treatment and prognosis are not known. We report a study
of 37 patients with small cell lung cancer (SCLC). Estima-
tions of thrombin activity and plasmin-mediated fibrinolysis
were obtained by measurement of plasma concentrations of
the fibrinopeptides A (FpA) and B/ 15-42 antigen (B,B)
respectively. There was evidence for increased thrombin
activity (median FpA was 13.2 molml-1 [normal
<4pmolml-1]) but only modestly increased fibrinolysis
(median Bf was 5.4pmolml-1 [normal <3 pmolml-1]).
Furthermore, the ratio of thrombin generation to fibrinolysis
(FpA/B,B ratio) was raised at 2.2 (normal < 1.3). Twenty-six
of these patients completed induction chemotherapy and
were evaluable for response: 14 complete responders, 7
partial responders and 5 non-responders. There was a signifi-
cant association between increased thrombin activity (FpA
levels) and lack of response to chemotherapy (P<0.01,
Mann-Whitney U-test). In addition non-responders had
evidence of an increased ratio of thrombin generation to
fibrinolysis (P<0.05, Mann-Whitney U-test). We studied the
same haemostatic parameters in 9 patients who have been in
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for SCLC. In this group median FpA was normal, at
3.3pmolml-1, and although median B,B was modestly ele-
vated (7.1 pmolml-1), the median FpA/Bfl ratio was normal
(0.41). The difference in thrombin activity and also in the
ratio of thrombin generation to fibrinolysis between these
two groups was significant (P<0.001, Mann-Whitney U-
test). This is the first study in cancer patients to show a
relationship between increased thrombin activity and a lack
of response to chemotherapy.
Structural changes in cytokeratin intermediate filaments
during in vivo epithelial preneoplasia
F.H. White & K. Gohari
Department of Anatomy, University of Hong Kong, Hong
Kong.
Cytokeratin filaments are intermediate filaments found in
epithelial tissues which become concentrated in the super-
ficial squames of keratinised epithelia. During malignant
transformation in such epithelia, abnormal intraepithelial
keratinisation, or dyskeratosis, is common. In this report, we
establish the quantitative characteristics of cytokeratin aggre-
gates in hamster cheek pouch epithelium treated with the
carcinogen DMBA. Such treatment produces hyperplastic
and dysplastic lesions prior to overt neoplasia.
Tissue samples from 5 animals each with dysplastic and
hyperplastic lesions were processed for electron microscopy.
Five untreated animals were used as controls. Volume
density measurements of cytokeratin filament aggregates
were determined by stereological procedures in defined basal,
spinous and granular compartments of the epithelium.
Determination of cellular volumes for each compartment
enabled the density data to be transformed to average cell
values.
Volume densities of filaments were similar in carcinogen-
treated epithelia when compared with normal epithelia, but
average cell volumes of filaments in each compartment
increased progressively following carcinogen treatment. We
conclude that carcinogen-induced preneoplastic lesions are
accompanied by increased synthesis of cytokeratins, which
may be related to the premature abnormal keratinisation so
frequently seen in dysplastic epithelium.